Method for generating trivalent antibody expressing cells by targeted integration of multiple expression cassettes in a defined tissue format
By using dual recombinase-mediated cassette exchange technology in mammalian cells to target and integrate specific expression cassette sequences, the problems of positional effects and expression instability caused by random integration were solved, enabling efficient and stable production of trivalent antibodies.
Patent Information
- Application Number
- CN202080044538.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2019-06-19
- Filing Date
- 2020-06-17
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2040-06-17
AI Technical Summary
Existing technologies for randomly integrating coding polypeptide sequences into recombinant cells suffer from problems such as positional effects, difficulty in copy number control, time-consuming and laborious screening, unstable polypeptide expression, and sequence variations. In particular, it is difficult to achieve efficient and stable expression and secretion when producing complex polypeptides.
The dual recombinase-mediated cassette exchange (RMCE) method was used to target and integrate specific expression cassette sequences into the mammalian cell genome, ensuring that the different expression cassettes of the heteropolymeric trivalent antibody are arranged in an orderly manner in the 5' to 3' direction, achieving stable integration and efficient expression.
This approach enables efficient recombinant expression and high-yield production of trivalent antibodies, ensuring proper assembly and secretion of peptides, resolving positional effects and expression instability issues caused by random integration, and improving production efficiency.
Smart Images

Figure CN114008212B_ABST
Abstract
Description
[0001] The present invention belongs to the field of cell line generation and polypeptide production. More precisely, recombinant mammalian cells are reported herein, which have been obtained by a double recombinase-mediated cassette exchange reaction, resulting in the integration of specific expression cassette sequences into the genome of the mammalian cells. The cells can be used in a method for producing trivalent antibodies. Background Art
[0002] Secreted and glycosylated polypeptides, such as antibodies, are often produced by recombinant expression (either stable or transient) in eukaryotic cells.
[0003] One strategy for producing recombinant cells expressing exogenous polypeptides of interest involves random integration of nucleotide sequences encoding polypeptides of interest, followed by a selection step and a separation step. However, this method has several disadvantages. First, the functional integration of nucleotide sequences into the cell genome is not only a rare event, but also, given the randomness of nucleotide sequence integration, these rare events lead to a variety of gene expression phenotypes and cell growth phenotypes. Such changes are called "position effect changes", which are at least partly derived from the complex gene regulatory network present in the eukaryotic cell genome and the accessibility of certain genomic loci for integration and gene expression. Second, random integration strategies generally cannot provide control over the number of copies of nucleotide sequences integrated into the cell genome. In fact, gene amplification methods are usually used to obtain high-yield cells. However, this gene amplification may also lead to unwanted cell phenotypes, such as unstable cell growth and / or product expression. Third, due to the inherent heterogeneity of the integration loci in the random integration process, it is time-consuming and laborious to screen thousands of cells after transfection to separate those recombinant cells that show the desired expression level of the polypeptide of interest. Even after isolating such cells, stable expression of the polypeptide of interest cannot be guaranteed, and further screening may be required to obtain stable commercial production cells. Fourth, polypeptides produced by cells obtained by random integration exhibit a high degree of sequence variation, which may be due in part to the mutagenicity of the selection agents used to select for high levels of polypeptide expression. Finally, the higher the complexity of the polypeptide to be produced, i.e., the higher the number of different polypeptides or polypeptide chains required to form the polypeptide of interest within the cell, the more important it is to control the expression ratio of the different polypeptides or polypeptide chains to each other. This expression ratio needs to be controlled so that the polypeptide of interest can be efficiently expressed, correctly assembled, and successfully secreted at a high expression yield.
[0004] Targeted integration by recombinase-mediated cassette exchange (RMCE) is a method to specifically and efficiently direct foreign DNA to a predetermined site in the genome of a eukaryotic host (Turan et al., J. Mol. Biol. 407 (2011) 193-221).
[0005] WO 2006 / 007850 discloses anti-rhesus D recombinant polyclonal antibodies and methods of production using site-specific integration into the genome of individual host cells.
[0006] Crawford, Y., et al. (Biotechnol. Prog. 29 (2013) 1307-1315) reported the use of a combination of phiC31 integrase and CRE-Lox technology to rapidly identify authentic hosts for target cell line development from limited genomic screening.
[0007] WO 2013 / 006142 discloses a nearly homogeneous population of genetically altered eukaryotic cells having stably incorporated into their genome a donor cassette comprising a strong polyadenylation site operably linked to an isolated nucleic acid fragment comprising a targeting nucleic acid site and a selectable marker protein encoding sequence, wherein the isolated nucleic acid fragment is flanked by a first recombination site and a different second recombination site.
[0008] WO 2018 / 162517 discloses that depending on i) the expression cassette sequence and ii) the distribution of the expression cassette between different expression vectors, high variations in expression yield and product quality were observed.
[0009] Tadauchi, T., et al. disclosed the use of a regulated targeted integration cell line development method to systematically study the reasons why antibodies are difficult to express (Biotechnol. Prog. 35 (2019) No. 2, 1-11).
[0010] WO 2016 / 079076 discloses T cell activating bispecific antigen binding molecules for FolR1 and CD3. In Example 29, the production of bispecific FolR1 / CD3-κ-λ antibodies is described, using transient transfection and a plasmid ratio of 1:1:1 for three expression vectors. In Example 36, the preparation of DP47 GS TCB is described by co-transfecting HEK293-EBNA cells with the corresponding expression vectors, with a ratio of 1:2:1:1 ("Carrier Heavy Chain Fc (hole)": "Carrier Light Chain": "Carrier Light Chain CrossFab": "Carrier Heavy Chain Fc (knob)-Fab CrossFab"). Similar disclosures are provided in WO 2017 / 055389 and WO 2016 / 020309.
[0011] WO 2014 / 033074 discloses a blood-brain barrier shuttle vector. In Example 2, it is disclosed that three expression plasmids with equimolar plasmid ratios were used during transfection to transiently produce trivalent MAb31-scFab (8D3).
[0012] WO 2017 / 184831 purportedly discloses site-specific integration and expression of recombinant proteins in eukaryotic cells, in particular by using expression enhancing loci to improve the expression of antibodies, including bispecific antibodies, in eukaryotic cells, in particular Chinese hamster (Cricetulus griseus) cell lines. The data in the article are presented in an anonymous manner, so no conclusions can be drawn about what is actually displayed.
[0013] Rajendra, Y., et al. disclosed that a single quaternary vector is a simple and effective alternative for generating stable CHO cell lines and can accelerate the generation of cell lines for clinical heterologous mAb therapy (Biotechnol. Prog. 33 (2017) 469-477). Summary of the invention
[0014] This article reports recombinant mammalian cells expressing trivalent antibodies, specifically bispecific trivalent antibodies, such as T cell bispecific antibodies (TCB). Trivalent antibodies are heteromultimeric polypeptides that are not naturally expressed by the mammalian cells. More specifically, trivalent antibodies are heteromultimeric proteins composed of four polypeptides or polypeptide chains: a light chain, which is a full-length light chain; another light chain, which is a domain-exchanged light chain; a heavy chain, which is a full-length heavy chain; and another heavy chain, which is an extended heavy chain containing an additional domain-exchanged heavy chain or light chain Fab fragment. In order to achieve the expression of trivalent antibodies, a recombinant nucleic acid containing multiple different expression cassettes in a specific and defined sequence has been integrated into the genome of a mammalian cell.
[0015] In particular, the method according to the invention can be used to generate T cell bispecific antibodies (TCBs). These can have the formats described, for example, in WO 2013 / 026831. These molecules can simultaneously bind to CD3 on T cells (first specificity) and to an antigen on a target (e.g., tumor) cell (second specificity), thereby inducing killing of the target cell.
[0016] Also reported herein is a method for producing a recombinant mammalian cell expressing a trivalent antibody, particularly a trivalent bispecific antibody, more particularly a TCB, and a method for producing a trivalent antibody, particularly a trivalent bispecific antibody, more particularly a TCB using the recombinant mammalian cell.
[0017] In a preferred embodiment, the bispecific trivalent antibody comprises
[0018] a) a first and a second Fab fragment each specifically binding to a first antigen,
[0019] b) a domain-swapped Fab fragment, in which the CH1 and CL domains are exchanged with each other, which specifically binds to a second antigen,
[0020] c) an Fc region comprising a first heavy chain Fc-region polypeptide and a second heavy chain Fc-region polypeptide,
[0021] wherein the C-terminus of the CH1 domain of the first Fab fragment is linked to the N-terminus of the heavy chain Fc region polypeptide, and the C-terminus of the CL domain of the domain-exchanged Fab fragment is linked to the N-terminus of the other heavy chain Fc region polypeptide, and
[0022] wherein the C-terminus of the CH1 domain of the second Fab fragment is connected to the N-terminus of the VH domain of the first Fab fragment or to the N-terminus of the VH domain of the domain-exchanged Fab fragment, and
[0023] The first antigen or the second antigen is human CD3.
[0024] In a preferred embodiment, the bispecific trivalent antibody comprises
[0025] a) a first and a second Fab fragment each specifically binding to a first antigen,
[0026] b) a domain-swapped Fab fragment, in which the VH and VL domains are exchanged for each other, which specifically binds to a second antigen,
[0027] c) an Fc region comprising a first heavy chain Fc-region polypeptide and a second heavy chain Fc-region polypeptide,
[0028] wherein the C-terminus of the CH1 domain of the first Fab fragment is linked to the N-terminus of the heavy chain Fc region polypeptide, and the C-terminus of the CH1 domain of the domain-exchanged Fab fragment is linked to the N-terminus of the other heavy chain Fc region polypeptide, and
[0029] wherein the C-terminus of the CH1 domain of the second Fab fragment is connected to the N-terminus of the VH domain of the first Fab fragment or to the N-terminus of the VL domain of the domain-exchanged Fab fragment, and
[0030] The first antigen or the second antigen is human CD3.
[0031] In a preferred embodiment, the first and second light chains of the trivalent bispecific antibody are not common light chains or universal light chains.
[0032] The present invention is based, at least in part, on the discovery that the sequences of the different expression cassettes required for heteromultimeric trivalent antibody expression (i.e., the expression cassette organization) affect the expression yield of the trivalent antibody (eg, TCB) when integrated into the genome of a mammalian cell.
[0033] The present invention is based at least in part on the discovery that efficient recombinant expression and production of trivalent antibodies (eg, TCB) can be achieved by integrating nucleic acids encoding heteromultimeric trivalent antibodies (eg, TCB) organized in a specific expression cassette into the genome of mammalian cells.
[0034] It has been found that a defined expression cassette sequence can be advantageously integrated into the genome of mammalian cells by a dual recombinase-mediated cassette exchange reaction.
[0035] According to one aspect of the present invention is a method for producing a trivalent antibody (e.g., TCB), the method comprising the following steps:
[0036] a) optionally culturing a mammalian cell comprising a deoxyribonucleic acid encoding the trivalent antibody (eg, TCB) under conditions suitable for expressing the trivalent antibody (eg, TCB), and
[0037] b) recovering the trivalent antibody (e.g. TCB) from the cells or culture medium,
[0038] wherein the deoxyribonucleic acid encoding the trivalent antibody (eg, TCB) is stably integrated into the genome of the mammalian cell and comprises in the 5' to 3' direction
[0039] or 1)
[0041] - a first expression cassette encoding a first heavy chain,
[0042] - a second expression cassette encoding a first light chain,
[0043] - a third expression cassette encoding the first light chain,
[0044] - a fourth expression cassette encoding the second heavy chain,
[0045] - a fifth expression cassette encoding a second light chain, and
[0046] -optionally, a sixth expression cassette encoding a second light chain,
[0047] or 2)
[0049] - a first expression cassette encoding a first light chain,
[0050] - a second expression cassette encoding a first light chain,
[0051] - a third expression cassette encoding the first heavy chain,
[0052] - a fourth expression cassette encoding the second heavy chain,
[0053] - a fifth expression cassette encoding a second light chain, and
[0054] - a sixth expression cassette encoding the second light chain,
[0055] The first to third expression cassettes are arranged in one direction, and the fourth to sixth expression cassettes are arranged in one direction and in the opposite direction to the first to third expression cassettes;
[0056] or 3)
[0058] - a first expression cassette encoding a first heavy chain,
[0059] - a second expression cassette encoding a first light chain,
[0060] - a third expression cassette encoding a second light chain,
[0061] - a fourth expression cassette encoding the second heavy chain,
[0062] - a fifth expression cassette encoding a second light chain, and
[0063] - a sixth expression cassette encoding the first light chain,
[0064] or
[0065] - a first expression cassette encoding a first heavy chain,
[0066] - a second expression cassette encoding a first light chain,
[0067] - a third expression cassette encoding a second light chain,
[0068] - a fourth expression cassette encoding the second heavy chain,
[0069] - a fifth expression cassette encoding a second light chain, and
[0070] - a sixth expression cassette encoding the second light chain.
[0071] In a preferred embodiment, the first heavy chain comprises the mutation T366W in the CH3 domain (according to Kabat numbering) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (according to Kabat numbering). In one embodiment, one of the heavy chains further comprises the mutation S354C, and the corresponding other heavy chain comprises the mutation Y349C (according to Kabat numbering). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain exchange Fab fragment. In one embodiment, the first light chain is a domain exchange light chain.
[0072] In one embodiment, the DNA comprises an additional expression cassette between the first and second expression cassettes encoding the second heavy chain.
[0073] In one embodiment
[0074] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0075] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0076] - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and
[0077] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0078] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0079] In one embodiment
[0080] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain and a CH3 domain,
[0081] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0082] - the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and
[0083] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0084] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0085] In one embodiment, the deoxyribonucleic acid is stably integrated into the genome of the mammalian cell at a single site or locus.
[0086] One aspect of the present invention is a deoxyribonucleic acid encoding a trivalent antibody (eg, TCB) comprising in the 5' to 3' direction
[0087] or 1)
[0089] - a first expression cassette encoding a first heavy chain,
[0090] - a second expression cassette encoding a first light chain,
[0091] - a third expression cassette encoding the first light chain,
[0092] - a fourth expression cassette encoding the second heavy chain,
[0093] - a fifth expression cassette encoding a second light chain, and
[0094] -optionally, a sixth expression cassette encoding a second light chain,
[0095] or 2)
[0097] - a first expression cassette encoding a first light chain,
[0098] - a second expression cassette encoding a first light chain,
[0099] - a third expression cassette encoding the first heavy chain,
[0100] - a fourth expression cassette encoding the second heavy chain,
[0101] - a fifth expression cassette encoding a second light chain, and
[0102] - a sixth expression cassette encoding the second light chain,
[0103] The first to third expression cassettes are arranged in one direction, and the fourth to sixth expression cassettes are arranged in one direction and in the opposite direction to the first to third expression cassettes;
[0104] or 3)
[0106] - a first expression cassette encoding a first heavy chain,
[0107] - a second expression cassette encoding a first light chain,
[0108] - a third expression cassette encoding a second light chain,
[0109] - a fourth expression cassette encoding the second heavy chain,
[0110] - a fifth expression cassette encoding a second light chain, and
[0111] - a sixth expression cassette encoding the first light chain,
[0112] or
[0113] - a first expression cassette encoding a first heavy chain,
[0114] - a second expression cassette encoding a first light chain,
[0115] - a third expression cassette encoding a second light chain,
[0116] - a fourth expression cassette encoding the second heavy chain,
[0117] - a fifth expression cassette encoding a second light chain, and
[0118] - a sixth expression cassette encoding the second light chain.
[0119] In a preferred embodiment, the first heavy chain comprises the mutation T366W in the CH3 domain (according to Kabat numbering) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (according to Kabat numbering). In one embodiment, one of the heavy chains further comprises the mutation S354C, and the corresponding other heavy chain comprises the mutation Y349C (according to Kabat numbering). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain exchange Fab fragment. In one embodiment, the first light chain is a domain exchange light chain.
[0120] In one embodiment, the DNA comprises an additional expression cassette between the first and second expression cassettes encoding the second heavy chain.
[0121] In one embodiment
[0122] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0123] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0124] - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and
[0125] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0126] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0127] In one embodiment
[0128] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain and a CH3 domain,
[0129] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0130] - the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and
[0131] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0132] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0133] One aspect of the present invention is a DNA sequence for expressing a trivalent antibody (eg, TCB) in a mammalian cell, the DNA sequence comprising in the 5' to 3' direction 1)
[0135] - a first expression cassette encoding a first heavy chain,
[0136] - a second expression cassette encoding a first light chain,
[0137] - a third expression cassette encoding the first light chain,
[0138] - a fourth expression cassette encoding the second heavy chain,
[0139] - a fifth expression cassette encoding a second light chain, and
[0140] -optionally, a sixth expression cassette encoding a second light chain,
[0141] or 2)
[0143] - a first expression cassette encoding a first light chain,
[0144] - a second expression cassette encoding a first light chain,
[0145] - a third expression cassette encoding the first heavy chain,
[0146] - a fourth expression cassette encoding the second heavy chain,
[0147] - a fifth expression cassette encoding a second light chain, and
[0148] - a sixth expression cassette encoding the second light chain,
[0149] The first to third expression cassettes are arranged unidirectionally, the fourth to sixth expression cassettes are arranged unidirectionally and aligned with the
[0150] The first to third expression cassettes are in opposite directions;
[0151] or 3)
[0153] - a first expression cassette encoding a first heavy chain,
[0154] - a second expression cassette encoding a first light chain,
[0155] - a third expression cassette encoding a second light chain,
[0156] - a fourth expression cassette encoding the second heavy chain,
[0157] - a fifth expression cassette encoding a second light chain, and
[0158] - a sixth expression cassette encoding the first light chain,
[0159] or
[0160] - a first expression cassette encoding a first heavy chain,
[0161] - a second expression cassette encoding a first light chain,
[0162] - a third expression cassette encoding a second light chain,
[0163] - a fourth expression cassette encoding the second heavy chain,
[0164] - a fifth expression cassette encoding a second light chain, and
[0165] - a sixth expression cassette encoding the second light chain.
[0166] In a preferred embodiment, the first heavy chain comprises the mutation T366W in the CH3 domain (according to Kabat numbering) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (according to Kabat numbering). In one embodiment, one of the heavy chains further comprises the mutation S354C, and the corresponding other heavy chain comprises the mutation Y349C (according to Kabat numbering). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain exchange Fab fragment. In one embodiment, the first light chain is a domain exchange light chain.
[0167] In one embodiment, the DNA comprises an additional expression cassette between the first and second expression cassettes encoding the second heavy chain.
[0168] In one embodiment
[0169] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0170] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0171] - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and
[0172] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0173] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0174] In one embodiment
[0175] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain and a CH3 domain,
[0176] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0177] - the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and
[0178] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0179] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0180] In one embodiment of the use, the deoxyribonucleic acid is integrated into the genome of the mammalian cell.
[0181] In one embodiment of this use, the deoxyribonucleic acid is stably integrated into the genome of the mammalian cell at a single site or locus.
[0182] One aspect of the invention is a recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent antibody (eg, TCB) integrated into the genome of the cell,
[0183] Wherein the deoxyribonucleic acid encoding the trivalent antibody (eg, TCB) comprises in the 5' to 3' direction or 1)
[0185] - a first expression cassette encoding a first heavy chain,
[0186] - a second expression cassette encoding a first light chain,
[0187] - a third expression cassette encoding the first light chain,
[0188] - a fourth expression cassette encoding the second heavy chain,
[0189] - a fifth expression cassette encoding a second light chain, and
[0190] -optionally, a sixth expression cassette encoding a second light chain,
[0191] or 2)
[0193] - a first expression cassette encoding a first light chain,
[0194] - a second expression cassette encoding a first light chain,
[0195] - a third expression cassette encoding the first heavy chain,
[0196] - a fourth expression cassette encoding the second heavy chain,
[0197] - a fifth expression cassette encoding a second light chain, and
[0198] - a sixth expression cassette encoding the second light chain,
[0199] The first to third expression cassettes are arranged in one direction, and the fourth to sixth expression cassettes are arranged in one direction and in the opposite direction to the first to third expression cassettes;
[0200] or 3)
[0202] - a first expression cassette encoding a first heavy chain,
[0203] - a second expression cassette encoding a first light chain,
[0204] - a third expression cassette encoding a second light chain,
[0205] - a fourth expression cassette encoding the second heavy chain,
[0206] - a fifth expression cassette encoding a second light chain, and
[0207] - a sixth expression cassette encoding the first light chain,
[0208] or
[0209] - a first expression cassette encoding a first heavy chain,
[0210] - a second expression cassette encoding a first light chain,
[0211] - a third expression cassette encoding a second light chain,
[0212] - a fourth expression cassette encoding the second heavy chain,
[0213] - a fifth expression cassette encoding a second light chain, and
[0214] - a sixth expression cassette encoding the second light chain.
[0215] In a preferred embodiment, the first heavy chain comprises the mutation T366W in the CH3 domain (according to Kabat numbering) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (according to Kabat numbering). In one embodiment, one of the heavy chains further comprises the mutation S354C, and the corresponding other heavy chain comprises the mutation Y349C (according to Kabat numbering). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain exchange Fab fragment. In one embodiment, the first light chain is a domain exchange light chain.
[0216] In one embodiment, the DNA comprises an additional expression cassette between the first and second expression cassettes encoding the second heavy chain.
[0217] In one embodiment of all of the aforementioned aspects and embodiments
[0218] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0219] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0220] - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and
[0221] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0222] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0223] In one embodiment of all of the aforementioned aspects and embodiments
[0224] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain and a CH3 domain,
[0225] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0226] - the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and
[0227] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0228] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0229] In one embodiment, the deoxyribonucleic acid is stably integrated into the genome of the mammalian cell at a single site or locus.
[0230] In one embodiment of all of the aforementioned aspects and embodiments, the deoxyribonucleic acid encoding the trivalent antibody (eg, TCB) further comprises
[0231] - a first recombination recognition sequence, which is located 5' to said first (most 5') expression cassette,
[0232] - a second recombination recognition sequence, which is located 3' to said sixth (most 3') expression cassette,
[0233] - a third recombination recognition sequence located at
[0234] - between the first recombination recognition sequence and the second recombination recognition sequence, and
[0235] - between two of the expression cassettes,
[0236] and
[0237] All recombination recognition sequences are different.
[0238] In one embodiment of all of the aforementioned aspects and embodiments, the third recombination recognition sequence is located between the third expression cassette and the fourth expression cassette.
[0239] In one embodiment of all of the aforementioned aspects and embodiments, the deoxyribonucleic acid encoding a trivalent antibody (e.g., TCB) comprises an additional expression cassette encoding a selection marker, and the expression cassette encoding the selection marker is partially located 5' of the third recombination recognition sequence and partially located 3' of the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal, wherein the start codon is operably linked to the coding sequence.
[0240] One aspect of the present invention is a composition comprising two DNAs, which in turn comprise three different recombination recognition sequences and six expression cassettes, wherein
[0241] - the first deoxyribonucleic acid comprises in the 5' to 3' direction
[0242] - a first recombination recognition sequence,
[0243] - a first expression cassette encoding a first heavy chain,
[0244] - a second expression cassette encoding a first light chain,
[0245] - a third expression cassette encoding the first light chain, and
[0246] - a first copy of the third recombination recognition sequence,
[0247] and
[0248] - the second deoxyribonucleic acid comprises in the 5' to 3' direction
[0249] - a second copy of the third recombination recognition sequence,
[0250] - a fourth expression cassette encoding the second heavy chain,
[0251] - a fifth expression cassette encoding the second light chain,
[0252] - a sixth expression cassette encoding the second light chain, and
[0253] - a second recombination recognition sequence.
[0254] In a preferred embodiment, the first heavy chain comprises the mutation T366W in the CH3 domain (according to Kabat numbering) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (according to Kabat numbering). In one embodiment, one of the heavy chains further comprises the mutation S354C, and the corresponding other heavy chain comprises the mutation Y349C (according to Kabat numbering). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain exchange Fab fragment. In one embodiment, the first light chain is a domain exchange light chain.
[0255] In one embodiment of all of the aforementioned aspects and embodiments
[0256] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0257] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0258] - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and
[0259] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0260] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0261] In one embodiment of all of the aforementioned aspects and embodiments
[0262] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain and a CH3 domain,
[0263] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0264] - the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and
[0265] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0266] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0267] In one embodiment of all of the aforementioned aspects and embodiments, the deoxyribonucleic acid encoding a trivalent antibody (eg, TCB) comprises an additional expression cassette encoding a selectable marker.
[0268] In one embodiment of all of the foregoing aspects and embodiments, the expression cassette encoding the selection marker is relative to the third recombination recognition sequence
[0269] i) located at 5', or
[0270] ii) located at the 3', or
[0271] iii) partly located at the 5' and partly located at the 3'.
[0272] In one embodiment of all of the aforementioned aspects and embodiments, the expression cassette encoding the selection marker is partially located 5' and partially located 3' of the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal.
[0273] In one embodiment of all the aforementioned aspects and embodiments, the 5' portion of the expression cassette encoding the selection marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is flanked upstream by a third expression cassette (i.e., positioned downstream of the third expression cassette), and the start codon is flanked downstream by a third recombination recognition sequence (i.e., positioned upstream of the third recombination recognition sequence); and the 3' portion of the expression cassette encoding the selection marker comprises a nucleic acid encoding a selection marker, which lacks a start codon and is flanked upstream by a third recombination recognition sequence and downstream by a fourth expression cassette.
[0274] In one embodiment of all the aforementioned aspects and embodiments, the start codon is a transcription start codon. In one embodiment, the start codon is ATG.
[0275] One aspect of the invention is a recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent antibody (eg, TCB) integrated into the genome of the cell,
[0276] The deoxyribonucleic acid encoding the trivalent antibody (eg, TCB) comprises the following elements:
[0277] a first recombination recognition sequence, a second recombination recognition sequence and a third recombination recognition sequence,
[0278] a first selectable marker and a second selectable marker, and
[0279] The first expression cassette to the sixth expression cassette,
[0280] The sequence of the element in the 5' to 3' direction is
[0281] RRS1-1 st EC-2 nd EC-3 rd EC-RRS3-SM1-4 th EC-5 th EC-6 th EC-RRS2
[0282] in
[0283] RRS = Recombination Recognition Sequence,
[0284] EC = expression cassette,
[0285] SM = selectable marker.
[0286] One aspect of the present invention is a method for producing a recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent antibody (eg, TCB) and secreting a trivalent antibody (eg, TCB), the method comprising the steps of:
[0287] a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of the mammalian cell, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence flanked by at least one first selection marker, and a third recombination recognition sequence located between the first recombination recognition sequence and the second recombination recognition sequence, and all of the recombination recognition sequences are different;
[0288] b) introducing into the cell provided in a) a composition of two deoxyribonucleic acids, the two deoxyribonucleic acids comprising three different recombination recognition sequences and six expression cassettes, wherein the first deoxyribonucleic acid comprises in the 5' to 3' direction
[0289] - a first recombination recognition sequence,
[0290] - a first expression cassette encoding a first heavy chain,
[0291] - a second expression cassette encoding a first light chain,
[0292] - a third expression cassette encoding the first light chain,
[0293] - the 5' part of the expression cassette encoding a second selectable marker, and
[0294] - a first copy of the third recombination recognition sequence,
[0295] and
[0296] The second deoxyribonucleic acid comprises in the 5' to 3' direction
[0297] - a second copy of the third recombination recognition sequence,
[0298] - the 3' part of the expression cassette encoding the second selectable marker,
[0299] - a fourth expression cassette encoding the second heavy chain,
[0300] - a fifth expression cassette encoding the second light chain,
[0301] - a sixth expression cassette encoding the second light chain, and
[0302] - a second recombination recognition sequence,
[0303] wherein the first to third recombination recognition sequences of the first deoxyribonucleic acid and the second deoxyribonucleic acid match the first to third recombination recognition sequences on the integrated exogenous nucleotide sequence,
[0304] wherein the 5' terminal portion and the 3' terminal portion of the expression cassette encoding one second selection marker when taken together form a functional expression cassette for said one second selection marker;
[0305] c)
[0306] i) is introduced simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b), or
[0307] ii) Then introduce
[0308] one or more recombinases,
[0309] wherein the one or more recombinases recognize the recombination recognition sequences of the first deoxyribonucleic acid and the second deoxyribonucleic acid; (and optionally wherein the one or more recombinases perform two recombinase-mediated cassette exchanges;)
[0310] as well as
[0311] d) selecting cells expressing a second selection marker and secreting a trivalent antibody (e.g. TCB),
[0312] Thereby, a recombinant mammalian cell is generated which contains a deoxyribonucleic acid encoding a trivalent antibody (eg, TCB) and secretes the trivalent antibody (eg, TCB).
[0313] In a preferred embodiment of all the aforementioned aspects and embodiments, the first heavy chain comprises the mutation T366W in the CH3 domain (according to Kabat numbering) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain, or vice versa (according to Kabat numbering). In one embodiment, one of the heavy chains further comprises the mutation S354C, and the respective other heavy chain comprises the mutation Y349C (according to Kabat numbering). In one embodiment, the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment.
[0314] In one embodiment of all of the aforementioned aspects and embodiments, the first light chain is a domain exchange light chain.
[0315] In one embodiment of all of the aforementioned aspects and embodiments
[0316] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0317] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0318] - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and
[0319] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0320] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0321] In one embodiment of all of the aforementioned aspects and embodiments
[0322] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain and a CH3 domain,
[0323] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0324] - the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and
[0325] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0326] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0327] In one embodiment of all the aforementioned aspects and embodiments, the expression cassette encoding the one second selection marker is partially located 5' and partially located 3' of the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises the coding sequence of the one second selection marker without a start codon and a poly A signal.
[0328] In one embodiment of all of the aforementioned aspects and embodiments, the 5' terminal portion of the expression cassette encoding the one second selection marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is flanked upstream by the expression cassette (i.e., positioned downstream of the expression cassette) and the start codon is flanked downstream by a third recombination recognition sequence (i.e., positioned upstream of the third recombination recognition sequence); and the 3' terminal portion of the expression cassette encoding the one second selection marker comprises the coding sequence of the one second selection marker, which coding sequence lacks a start codon and is flanked upstream by a third recombination recognition sequence and downstream by the expression cassette.
[0329] In one embodiment of all the aforementioned aspects and embodiments, the start codon is a translation start codon. In one embodiment, the start codon is ATG.
[0330] In one embodiment of all of the foregoing aspects and embodiments, the first deoxyribonucleic acid is integrated into a first vector and the second deoxyribonucleic acid is integrated into a second vector.
[0331] In one embodiment of all the aforementioned aspects and embodiments, each of the expression cassettes comprises, in the 5' to 3' direction, a promoter, a coding sequence and a polyadenylation signal sequence, optionally followed by a terminator sequence.
[0332] In one embodiment of all of the aforementioned aspects and embodiments
[0333] i) a first expression cassette comprising, in 5' to 3' direction, a promoter, a nucleic acid encoding a first heavy chain and a polyadenylation signal sequence, and optionally a terminator sequence,
[0334] ii) a second expression cassette comprising, in 5' to 3' direction, a promoter, the nucleic acid encoding the first light chain and a polyadenylation signal sequence, and optionally a terminator sequence,
[0335] iii) a third expression cassette comprises, in 5' to 3' direction, a promoter, the nucleic acid encoding the first light chain and a polyadenylation signal sequence, and optionally a terminator sequence,
[0336] iv) a fourth expression cassette comprising, in 5' to 3' direction, a promoter, the nucleic acid encoding the second heavy chain and a polyadenylation signal sequence, and optionally a terminator sequence,
[0337] v) a fifth expression cassette comprising, in 5' to 3' direction, a promoter, the nucleic acid encoding the second light chain and a polyadenylation signal sequence, and optionally a terminator sequence,
[0338] vi) a sixth expression cassette comprising, in the 5' to 3' direction, a promoter, the nucleic acid encoding the second light chain and a polyadenylation signal sequence, and optionally a terminator sequence, and
[0339] vii) The expression cassette encoding the selectable marker comprises, in the 5' to 3' direction, a promoter, the nucleic acid encoding the selectable marker and a polyadenylation signal sequence, and optionally a terminator sequence.
[0340] In one embodiment of all of the aforementioned aspects and embodiments, the promoter is human CMV promoter with or without intron A, the polyadenylation signal sequence is a bGH poly A site, and the terminator is a hGT terminator.
[0341] The terminator sequence prevents RNA polymerase II from producing very long RNA transcripts, i.e. reading through to the next expression cassette in the deoxyribonucleic acid according to the invention and being used in the method according to the invention. That is, the expression of a target structural gene is controlled by its own promoter.
[0342] Therefore, by the combination of polyadenylation signal and terminator sequence, efficient transcription termination is achieved. That is, the presence of double termination signal prevents the read-through of RNA polymerase II. The terminator sequence initiates complex disassembly and promotes the dissociation of RNA polymerase from DNA template.
[0343] In one embodiment of all of the aforementioned aspects and embodiments, for the expression cassette other than the selection marker, the promoter is the human CMV promoter with intron A, the polyadenylation signal sequence is the bGH polyadenylation signal sequence, and the terminator is the hGT terminator, for the expression cassette of the selection marker, wherein the promoter is the SV40 promoter, and the polyadenylation signal sequence is the SV40 polyadenylation signal sequence and the terminator is absent.
[0344] In one embodiment of all of the foregoing aspects and embodiments, the mammalian cell is a CHO cell. In one embodiment, the CHO cell is a CHO-K1 cell.
[0345] In one embodiment of all aspects and embodiments the trivalent antibody is a therapeutic antibody.
[0346] In one embodiment of all aspects and embodiments, the bispecific (therapeutic) antibody (TCB) comprises
[0347] - a first Fab fragment and a second Fab fragment, wherein each binding site of the first Fab fragment and the second Fab fragment specifically binds to a second antigen,
[0348] - a third Fab fragment, wherein the binding site of the third Fab fragment specifically binds to the first antigen, and wherein the third Fab fragment comprises a domain crossover such that the variable light chain domain (VL) and the variable heavy chain domain (VH) are replaced with each other, and
[0349] - an Fc region comprising a first Fc region polypeptide and a second Fc region polypeptide,
[0350] wherein the first Fab fragment and the second Fab fragment each comprise a heavy chain fragment and a full-length light chain,
[0351] wherein the C-terminus of the heavy chain fragment of the first Fab fragment is fused to the N-terminus of the first Fc region polypeptide,
[0352] The C-terminus of the heavy chain fragment of the second Fab fragment is fused to the N-terminus of the variable light chain domain of the third Fab fragment, and the C-terminus of the heavy chain constant domain 1 of the third Fab fragment is fused to the N-terminus of the second Fc region polypeptide.
[0353] In one embodiment of all aspects and embodiments herein, at least one selectable marker expression cassette is in the opposite orientation to the antibody heavy and light chain expression cassettes.
[0354] In one embodiment of all aspects and embodiments herein, the antibody heavy and light chain expression cassettes are unidirectionally arranged relative to each other (ie, have the same 3'- to 5'-direction orientation), and at least one selectable marker expression cassette is bidirectionally arranged relative to the antibody heavy and light chain expression cassettes.
[0355] In one embodiment of all aspects and embodiments, the trivalent antibody is an anti-CD3 / CD20 bispecific antibody. In one embodiment, the anti-CD3 / CD20 bispecific antibody is a TCB with CD20 as the second antigen. In one embodiment, the bispecific anti-CD3 / CD20 antibody is RG6026. Such antibodies are reported in WO 2016 / 020309, which is incorporated herein by reference in its entirety.
[0356] In one embodiment of all aspects and embodiments, the trivalent antibody is an anti-CD3 / CEA bispecific antibody. In one embodiment, the anti-CD3 / CEA bispecific antibody is a TCB with CEA as the second antigen. In one embodiment, the bispecific anti-CD3 / CEA antibody is RO6958688 or RG7802 or cibisatamab. Such antibodies are reported in WO2017 / 055389, which is incorporated herein by reference in its entirety.
[0357] In one embodiment of all of the aforementioned aspects and embodiments, neither the first light chain nor the second light chain of the trivalent bispecific antibody is a common light chain or a universal light chain.
[0358] In one embodiment of all of the aforementioned aspects and embodiments, the second heavy chain variable domain and the first light chain variable domain form a first binding site and the first heavy chain variable domain and the second light chain variable domain form a second binding site.
[0359] In a preferred embodiment of all aspects and embodiments, the first binding site specifically binds human CD3.
[0360] In a preferred embodiment of all aspects and embodiments, the second binding site specifically binds human CD3.
[0361] In a preferred embodiment of all aspects and embodiments, exactly two deoxyribonucleic acids are comprised or introduced.
[0362] The individual expression cassettes in the deoxyribonucleic acid according to the invention are arranged sequentially. The distance between the end of one expression cassette and the start of the following expression cassette is only a few nucleotides, which is required by the cloning process, i.e. the result of the cloning process.
[0363] In one embodiment of all the aforementioned aspects and embodiments, two immediately following expression cassettes are at most 100 bps apart (i.e., starting from the end of the poly A signal sequence or the terminator sequence, up to the start of the immediately following promoter element is at most 100 base pairs (bps)). In one embodiment, two immediately following expression cassettes are at most 50 bps apart. In a preferred embodiment, two immediately following expression cassettes are at most 25 bps apart. BRIEF DESCRIPTION OF THE DRAWINGS
[0364] Figure 1 : Scheme of the two-plasmid RMCE strategy, which involves using three RRS sites to perform two independent RMCEs simultaneously. DETAILED DESCRIPTION
[0365] The present invention is based at least in part on the discovery that the use of a defined and specific expression cassette organization format for the expression of trivalent antibodies (e.g., TCB) (complex molecules comprising different polypeptides, i.e., heteromultimers) results in efficient expression and production of trivalent antibodies (e.g., TCB) in mammalian cells (such as CHO cells).
[0366] The present invention is based at least in part on the discovery that dual recombinase-mediated cassette exchange (RMCE) can be used to generate recombinant mammalian cells, such as recombinant CHO cells, in which a defined and specific expression cassette sequence has been integrated into the genome, which in turn leads to efficient expression and production of trivalent antibodies (e.g., TCB). The integration is achieved by targeted integration at a specific site in the mammalian cell genome. Thus, it is possible to control the expression ratio of different polypeptides of a heteromultimeric trivalent antibody (e.g., TCB) relative to each other. Thus, efficient expression, correct assembly and successful secretion of correctly folded and assembled trivalent antibodies (e.g., TCB) are achieved with high expression yields.
[0367] I. Definitions
[0368] Methods and techniques that can be used to practice the present invention are described, for example, in Ausubel, FM (ed.), Current Protocols in Molecular Biology, Vol. I to Vol. III (1997); Glover, ND and Hames, BD, ed., DNA Cloning: A Practical Approach, Vol. I and Vol. II (1985), Oxford University Press; Freshney, RI (ed.), Animal Cell Culture—a practical approach, IRL Press Limited (1986); Watson, JD et al., Recombinant DNA, 2nd ed., CHSLPress (1992); Winnacker, EL, From Genes to Clones; NY, VCH Publishers (1987); Celis, J., ed., Cell Biology, 2nd ed., Academic Press (1998); Freshney, RI, Culture of Animal Cells: A Manual of Basic Technique, 2nd ed., Alan R. Liss, Inc., NY (1987).
[0369] Derivatives of nucleic acids can be generated using recombinant DNA technology. Such derivatives can be modified, for example, by substitution, change, exchange, deletion or insertion at a single or several nucleotide positions. Modification or derivatization can be performed, for example, by means of site-directed mutagenesis. Such modifications can be easily performed by those skilled in the art (see, for example, Sambrook, J. et al., Molecular Cloning: A laboratory manual (1999) Cold Spring Harbor Laboratory Press, New York, USA; Hames, BD and Higgins, SG, Nucleic acid hybridization-apractical approach (1985) IRL Press, Oxford, England).
[0370] It must be noted that, as used herein and in the appended claims, the singular forms "a", "an", and "the" include plural references unless the context clearly dictates otherwise. Thus, for example, reference to "a cell" includes a plurality of such cells and equivalents thereof known to those skilled in the art, and so forth. Likewise, the terms "a", "one or more", and "at least one" may be used interchangeably herein. It should also be noted that the terms "comprising", "including", and "having" may be used interchangeably.
[0371] The term "about" means a range of + / -20% of the value that follows. In one embodiment, the term "about" means a range of + / -10% of the value that follows. In one embodiment, the term "about" means a range of + / -5% of the value that follows.
[0372] The term "comprising" also encompasses the term "consisting of".
[0373] The term "CD20-TCB" as used herein refers to a TCB targeting CD20 (CD20-TCB; RG6026; anti-CD3 / CD20 antibody in TCB format) that has a long half-life and high potency, which is achieved by high-affinity bivalent binding to CD20 and the head-to-tail orientation of the B and T cell binding domains in a previously characterized 2:1 TCB molecule format (see, e.g., Bacac, M. et al. Clin. Cancer Res. 22 (2016) 3286–3297; Bacac, M. et al. Oncoimmunology 5 (2016) e1203498).
[0374] The term "mammalian cell comprising an exogenous nucleotide sequence" encompasses cells into which one or more exogenous nucleic acids (including progeny of such cells) have been introduced and which are intended to form the starting point for further genetic modification. Therefore, the term "mammalian cell comprising an exogenous nucleotide sequence" encompasses cells comprising an exogenous nucleotide sequence integrated at a single site within the locus of the mammalian cell genome, wherein the exogenous nucleotide sequence at least comprises a first recombination recognition sequence and a second recombination recognition sequence flanking at least one first selective marker (these recombinase recognition sequences are different). In one embodiment, the mammalian cell comprising an exogenous nucleotide sequence is a cell comprising an exogenous nucleotide sequence integrated at a single site within the locus of the host cell genome, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence flanking at least one first selective marker, and a third recombination recognition sequence between the first recombination recognition sequence and the second recombination recognition sequence, and all recombination recognition sequences are different.
[0375] As used herein, the term "recombinant cell" refers to a cell that has been genetically modified, such as, for example, a cell that expresses a polypeptide of interest and can be used to produce the polypeptide of interest on any scale. For example, a "mammalian cell comprising an exogenous nucleotide sequence" that has been subjected to recombinase-mediated cassette exchange (RMCE) whereby the coding sequence for a polypeptide of interest has been introduced into the genome of the host cell is a "recombinant cell". Although the cell is still capable of further RMCE reactions, it is not desirable to do so.
[0376] "Mammalian cells comprising exogenous nucleotide sequences" and "recombinant cells" are both "transformed cells". The term includes the primary transformed cell and progeny derived therefrom, without regard to the number of passages. Progeny may, for example, not be completely identical to the nucleic acid content of the parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as screened or selected for in the originally transformed cell are encompassed.
[0377] An "isolated" composition is one that has been separated from the components of its natural environment. In some embodiments, the composition is purified to a purity greater than 95% or 99%, as determined by, for example, electrophoresis (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis, CE-SDS) or chromatography (e.g., size exclusion chromatography or ion exchange or reversed phase HPLC). For a review of methods for assessing, for example, antibody purity, see Flatman, S. et al., J. Chrom. B 848 (2007) 79-87.
[0378] An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in a cell that normally contains the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.
[0379] An "isolated" polypeptide or antibody is one that has been separated from a component of its natural environment.
[0380] The term "integration site" refers to a nucleic acid sequence in a cell genome into which an exogenous nucleotide sequence has been inserted. In certain embodiments, the integration site is between two adjacent nucleotides in the cell genome. In certain embodiments, the integration site comprises a nucleotide sequence. In certain embodiments, the integration site is located in a specific locus of the genome of a mammalian cell. In certain embodiments, the integration site is in an endogenous gene of a mammalian cell.
[0381] As used herein, the terms "vector" or "plasmid" (used interchangeably) refer to a nucleic acid molecule capable of transporting another nucleic acid to which it is linked. The term includes vectors that are self-replicating nucleic acid structures, as well as vectors that are incorporated into the genome of a host cell into which they have been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operably linked. Such vectors are referred to herein as "expression vectors."
[0382] The term "binding to" refers to the binding of a binding site to its target, such as the binding of an antibody binding site comprising an antibody heavy chain variable domain and an antibody light chain variable domain to a corresponding antigen. This binding can be accomplished using, for example, Assay (GE Healthcare, Uppsala, Sweden). That is, the term "binding (to an antigen)" means that the antibody binds to its antigen in an in vitro assay. In one embodiment, binding is determined in a binding assay, in which the antibody is bound to a surface and the binding of the antigen to the antibody is measured by surface plasmon resonance (SPR). Binding means, for example, binding affinity (K D ) is 10 -8 M or less, in some embodiments 10 -13 M to 10 -8 M, in some embodiments, is 10 -13 M to 10 -9 M. The term "binding" also includes the term "specific binding".
[0383] For example, in In one possible embodiment of the assay, the antigen is bound to a surface and the binding of the antibody (i.e., its binding site) is measured by surface plasmon resonance (SPR). The affinity of the binding is measured by the term k a (Association constant: rate constant for association to form a complex), k d (dissociation constant: rate constant for complex dissociation) and K D (k d / k a Alternatively, the binding signal of the SPR sensorgram can be directly compared with the response signal of a reference in terms of resonance signal height and dissociation behavior.
[0384] The term "binding site" refers to any protein entity that exhibits binding specificity for a target. This can be, for example, a receptor, a receptor ligand, anticalin, affibody, antibody, etc. Thus, the term "binding site" as used herein refers to a polypeptide that can specifically bind to or can be specifically bound by a second polypeptide.
[0385] As used herein, the term "selective marker" refers to a gene that allows specific selection or exclusion of cells carrying the gene in the presence of a corresponding selective agent. For example, but not limited to, a selective marker can allow positive selection of host cells transformed with the selective marker gene in the presence of a corresponding selective agent (selective culture conditions); untransformed host cells will not be able to grow or survive under the selective culture conditions. Selective markers can be positive, negative or bifunctional. Positive selective markers can allow selection of cells carrying the marker, while negative selective markers can allow selective elimination of cells carrying the marker. Selective markers can confer resistance to drugs, or compensate for metabolic or catabolism defects in host cells. In prokaryotic cells, genes that confer resistance to ampicillin, tetracycline, kanamycin or chloramphenicol, as well as other genes, can be used. Resistance genes that can be used as selectable markers in eukaryotic cells include, but are not limited to, genes for aminoglycoside phosphotransferases (APHs) (e.g., hygromycin phosphotransferase (HYG), neomycin and G418 APH), dihydrofolate reductase (DHFR), thymidine kinase (TK), glutamine synthetase (GS), asparagine synthetase, tryptophan synthetase (indole), histidinol dehydrogenase (histidinol D), and genes encoding resistance to puromycin, blasticidin, bleomycin, phleomycin, chloramphenicol, Zeocin and mycophenolic acid. Additional marker genes are described in WO 92 / 08796 and WO 94 / 28143.
[0386] In addition to facilitating selection in the presence of a corresponding selective agent, a selectable marker may alternatively be a molecule that is not normally present in the cell, such as green fluorescent protein (GFP), enhanced GFP (eGFP), synthetic GFP, yellow fluorescent protein (YFP), enhanced YFP (eYFP), cyan fluorescent protein (CFP), mPlum, mCherry, tdTomato, mStrawberry, J-red, DsRed monomer, mOrange, mKO, mCitrine, Venus, YPet, Emerald, CyPet, mCFPm, Cerulean, and T-Sapphire. Cells expressing such a molecule can be distinguished from cells not containing the gene, for example, by detecting fluorescence emitted by the encoded polypeptide or the absence of such fluorescence, respectively.
[0387] As used herein, the term "operably connected" refers to the juxtaposition of two or more components, wherein the relationship of these components allows them to play a role in an expected manner. For example, if a promoter and / or an enhancer are used to regulate the transcription of a coding sequence, the promoter and / or the enhancer are operably connected to the coding sequence. In certain embodiments, the DNA sequence of "operably connected" is connected and adjacent on a single chromosome. In certain embodiments, for example, when two protein coding regions (such as a secretory leader and a polypeptide) must be joined, these sequences are connected, adjacent, and in the same reading frame. In certain embodiments, the promoter that is operably connected is located upstream of the coding sequence and can be adjacent to the coding sequence. In certain embodiments, for example, about the enhancer sequence that regulates the expression of the coding sequence, these two components can be operably connected, but are not adjacent. If an enhancer increases the transcription of a coding sequence, the enhancer is operably connected to the coding sequence. The enhancer that is operably connected can be located upstream, inside or downstream of the coding sequence, and can be located at a position quite far away from the promoter of the coding sequence. Operable connection can be accomplished by recombination methods known in the art (e.g., using PCR methods and / or by connecting at convenient restriction sites). If there is no convenient restriction site, synthetic oligonucleotide adapters or joints can be used according to conventional practice. If an internal ribosome entry site (IRES) allows translation of the ORF to be initiated at an internal position independent of the 5' end, the IRES is operably connected to the open reading frame (ORF).
[0388] As used herein, the term "flanking" refers to a first nucleotide sequence being located at the 5' end or the 3' end or both ends of a second nucleotide sequence. The flanking nucleotide sequence may be adjacent to or at a defined distance from the second nucleotide sequence. The length of the flanking nucleotide sequence is not specifically limited. For example, the flanking sequence may have a few base pairs or several thousand base pairs.
[0389] Deoxyribonucleic acid comprises a coding strand and a non-coding strand. The terms "5'" and "3'" when used herein refer to positions on the coding strand.
[0390] As used herein, the term "exogenous" refers to a nucleotide sequence that is not derived from a specific cell, but is introduced into the cell by a DNA delivery method (e.g., by a transfection method, an electroporation method, or a transformation method). Therefore, an exogenous nucleotide sequence is an artificial sequence, wherein the artificiality can be derived from, for example, a combination of subsequences from different sources (e.g., a combination of a recombinase recognition sequence with an SV40 promoter and a coding sequence for a green fluorescent protein is an artificial nucleic acid) or from a sequence (e.g., only encoding the extracellular domain of a membrane-bound receptor or a sequence of a cDNA) or a partial deletion, or a nuclear base mutation. The term "endogenous" refers to a nucleotide sequence derived from a cell. An "exogenous" nucleotide sequence can have an "endogenous" counterpart with the same base composition, but wherein the "exogenous" sequence is, for example, introduced into a cell via recombinant DNA technology.
[0391] Antibody
[0392] General information on the nucleotide sequences of human immunoglobulin light and heavy chains is given in: Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991).
[0393] The term "heavy chain" is used herein in its original meaning, i.e., to refer to the two larger polypeptide chains of the four polypeptide chains that form an antibody (see, e.g., Edelman, GM and Gally JA, J. Exp. Med. 116 (1962) 207-227). The term "larger" in this context may refer to any of the molecular weight, length, and number of amino acids. The term "heavy chain" is independent of the sequence and number of individual antibody domains present therein. It is assigned only according to the molecular weight of the corresponding polypeptide.
[0394] The term "light chain" is used herein in its original meaning, i.e., to denote the smaller of the four polypeptide chains that form an antibody (see, e.g., Edelman, GM and Gally JA, J. Exp. Med. 116 (1962) 207-227). The term "smaller" in this context may refer to any of the molecular weight, length, and number of amino acids. The term "light chain" is independent of the sequence and number of individual antibody domains present therein. It is assigned only according to the molecular weight of the corresponding polypeptide.
[0395] As used herein, the amino acid positions of all constant regions and domains of heavy and light chains are numbered according to the Kabat numbering system described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), and are referred to herein as "numbered according to Kabat." Specifically, the Kabat numbering system (see Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) pp. 647-660) is used for the light chain constant domains CL of the kappa and lambda isotypes, and the EU index numbering system of Kabat (see Kabat, et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991) pp. 661-723) is used for the constant heavy chain domains (CH1, hinge, CH2 and CH3, which are further classified herein by being referred to in this context as "numbering according to the EU index of Kabat").
[0396] The term "antibody" herein is used in the broadest sense and encompasses various antibody structures including, but not limited to, full length antibodies, monoclonal antibodies, multispecific antibodies (eg, bispecific antibodies), and antibody-antibody fragment fusions, and combinations thereof.
[0397] The term "natural antibody" refers to naturally occurring immunoglobulin molecules with different structures. For example, a natural IgG antibody is a heterotetrameric glycoprotein of about 150,000 daltons, consisting of two identical light chains and two identical heavy chains bonded by disulfide bonds. From the N-terminus to the C-terminus, each heavy chain has a heavy chain variable region (VH), followed by three constant domains (CH1, CH2, and CH3), whereby the hinge region is positioned between the first heavy chain constant domain and the second heavy chain constant domain. Similarly, from the N-terminus to the C-terminus, each light chain has a light chain variable region (VL), followed by a light chain constant domain (CL). The light chain of an antibody can be classified into one of two types based on the amino acid sequence of its constant domain, which are called kappa (κ) and lambda (λ).
[0398] The term "full-length antibody" refers to an antibody having a structure substantially similar to that of a natural antibody. A full-length antibody comprises two or more full-length antibody light chains, each light chain comprising a variable region and a constant domain in the N- to C-terminal direction; and two heavy chains, each comprising a variable region, a first constant domain, a hinge region, a second constant domain, and a third constant domain in the N- to C-terminal direction. In contrast to natural antibodies, a full-length antibody may comprise additional immunoglobulin domains, for example, one or more additional scFvs, or heavy or light chain Fab fragments, or scFab conjugated to one or more ends of different chains of a full-length antibody, but only a single fragment is conjugated to each end. These conjugates are also encompassed by the term full-length antibody.
[0399] The term "antibody binding site" refers to a pair of heavy chain variable domains and light chain variable domains. In order to ensure the correct combination with the antigen, these variable domains are homologous variable domains, i.e., belong together. The antibody binding site comprises at least three HVRs (e.g., in the case of VHH) or three to six HVRs (e.g., in the case of natural existence, i.e., conventional antibodies with VH / VL pairs). Generally, the amino acid residues of the antibody responsible for antigen binding form the binding site. These residues are generally contained in a pair of antibody heavy chain variable domains and corresponding antibody light chain variable domains. For example, the antigen binding site of an antibody comprises amino acid residues from a complementary determining region or HVR. "Framework" or "FR" regions are those variable domain regions other than the hypervariable region residues defined herein. Therefore, the light chain and heavy chain variable domains of an antibody comprise regions FR1, HVR1, FR2, HVR2, FR3, HVR3, and FR4 from N-terminal to C-terminal. In particular, the HVR3 region of the heavy chain variable domain is the region that contributes the most to antigen binding, and defines the binding specificity of the antibody. A "functional binding site" is capable of specific binding to its target. The term "specific binding" refers to the binding of a binding site to its target in an in vitro assay in one embodiment of a binding assay. This binding assay can be any assay as long as a binding event can be detected. For example, in an assay where an antibody is bound to a surface, the binding of the antigen to the antibody is measured by surface plasmon resonance (SPR). Alternatively, a bridging ELISA can be used.
[0400] As used herein, the term "hypervariable region" or "HVR" refers to each of the following: regions of an antibody variable domain comprising stretches of amino acid residues that are hypervariable in sequence ("complementarity determining regions" or "CDRs") and / or form structurally defined loops ("hypervariable loops") and / or contain antigen contact residues ("antigen contact points"). Typically, an antibody comprises six HVRs; three in the heavy chain variable domain VH (H1, H2, H3), and three in the light chain variable domain VL (L1, L2, L3).
[0401] HVR includes
[0402] (a) hypervariable loops present at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2) and 96-101 (H3) (Chothia, C and Lesk, AM, J. Mol. Biol. 196 (1987) 901-917);
[0403] (b) CDRs present at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th Edition, Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242);
[0404] (c) antigenic contact points present at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al., J. Mol. Biol. 262:732-745 (1996)); and
[0405] (d) a combination of (a), (b) and / or (c), comprising amino acid residues 46-56 (L2), 47-56 (L2), 48-56 (L2), 49-56 (L2), 26-35 (H1), 26-35b (H1), 49-65 (H2), 93-102 (H3) and 94-102 (H3).
[0406] Unless otherwise indicated, HVR residues and other residues in the variable domain (eg, FR residues) are numbered herein according to Kabat et al., supra.
[0407] The "class" of an antibody refers to the type of constant domain or constant region, preferably Fc region, possessed by the heavy chain of the antibody. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and some of them can be further divided into subclasses (isotypes), e.g., IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.
[0408] The term "heavy chain constant region" refers to an immunoglobulin heavy chain region comprising a constant domain, i.e., for a natural immunoglobulin, a CH1 domain, a hinge region, a CH2 domain, and a CH3 domain, or for a full-length immunoglobulin, a first constant domain, a hinge region, a second constant domain, and a third constant domain. In one embodiment, the human IgG heavy chain constant region extends from Ala118 to the carboxyl terminus of the heavy chain (numbered according to the Kabat EU index). However, the C-terminal lysine (Lys447) of the constant region may be present or absent (numbered according to the Kabat EU index). The term "constant region" refers to a dimer comprising two heavy chain constant regions, which may be covalently linked to each other by hinge region cysteine residues to form an interchain disulfide bond.
[0409] The term "heavy chain Fc region" refers to the C-terminal region of an immunoglobulin heavy chain, which includes at least a portion of a hinge region (middle and lower hinge regions), a second constant domain, such as a CH2 domain, and a third constant domain, such as a CH3 domain. In one embodiment, the human IgG heavy chain Fc region extends from Asp221 or from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain (numbered according to the Kabat EU index). Therefore, the Fc region is smaller than the constant region but is identical to it in the C-terminal portion. However, the C-terminal lysine (Lys447) in the heavy chain Fc region may be present or absent (numbered according to the Kabat EU index). The term "Fc-region" refers to a dimer comprising two heavy chain Fc regions, which may be covalently linked to each other by hinge region cysteine residues to form an interchain disulfide bond.
[0410] The constant region of an antibody, more precisely the Fc region (and the same constant region) is directly involved in complement activation, C1q binding, C3 activation and Fc receptor binding. While the effect of an antibody on the complement system depends on certain conditions, binding to C1q is caused by a defined binding site in the Fc region. Such binding sites are known in the prior art and are described, for example, by Lukas, TJ et al., J. Immunol. 127 (1981) 2555-2560; Brunhouse, R. and Cebra, JJ, Mol. Immunol. 16 (1979) 907-917; Burton, DR et al., Nature 288 (1980) 338-344; Thommesen, JE et al., Mol. Immunol. 37 (2000) 995-1004; Idusogie, EE et al., J. Immunol. 164 (2000) 4178-4184; Hezareh, M. et al., J. Virol. 75 (2001) 12161-12168; Morgan, A. et al., Immunology 86 (1995) 319-324; and EP 0 307 434. Such binding sites are, for example, L234, L235, D270, N297, E318, K320, K322, P331 and P329 (numbered according to the Kabat EU index). Antibodies of subclasses IgG1, IgG2 and IgG3 generally exhibit complement activation, C1q binding and C3 activation, while IgG4 does not activate the complement system, does not bind C1q and does not activate C3. "Fc region of an antibody" is a term well known to the skilled person and is defined based on the cleavage of an antibody by papain.
[0411] The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantially homogeneous antibody population, that is, except for possible variant antibodies (e.g., containing naturally occurring mutations or produced during the production of monoclonal antibody preparations, such variants are usually presented in small amounts), each antibody comprising the population is identical and / or binds to the same epitope. Contrary to polyclonal antibody preparations that typically include different antibodies for different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed to a single determinant on an antigen. Therefore, the modifier "monoclonal" indicates that the characteristic of an antibody is obtained from a substantially homogeneous antibody population, and should not be interpreted as requiring antibodies to be produced by any particular method. For example, monoclonal antibodies can be prepared by a variety of techniques, including but not limited to hybridoma methods, recombinant DNA methods, phage display methods, and methods utilizing transgenic animals comprising all or part of a human immunoglobulin locus.
[0412] The term "valency" as used in this application indicates the presence of a specified number of binding sites in an antibody. Thus, the terms "bivalent", "tetravalent", and "hexavalent" indicate the presence of two binding sites, four binding sites, and six binding sites in an antibody, respectively.
[0413] "Monospecific antibody" means an antibody with a single binding specificity, specifically binding to one antigen. Monospecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g., F(ab')2) or combinations thereof (e.g., full-length antibodies plus additional scFv or Fab fragments). Monospecific antibodies do not need to be monovalent, i.e., monospecific antibodies may contain more than one binding site that specifically binds to one antigen. For example, natural antibodies are monospecific but bivalent.
[0414] "Multispecific antibody" means having binding specificity for at least two different epitopes or two different antigens on the same antigen. Multispecific antibodies can be prepared as full-length antibodies or antibody fragments (e.g., F(ab')2 bispecific antibodies) or combinations thereof (e.g., full-length antibodies plus additional scFv or Fab fragments). Multispecific antibodies are at least bivalent, i.e., contain two antigen binding sites. In addition, multispecific antibodies are at least bispecific. Therefore, bivalent bispecific antibodies are the simplest form of multispecific antibodies. Engineered antibodies with two, three or more (e.g., four) functional antigen binding sites have also been reported (see, e.g., US 2002 / 0004587 A1).
[0415] In certain embodiments, the antibody is a multispecific antibody, such as at least a bispecific antibody. A multispecific antibody is a monoclonal antibody that has binding specificities for at least two antigens or epitopes. In certain embodiments, one of the binding specificities is for a first antigen, and the other is for a different second antigen. In certain embodiments, a multispecific antibody can bind to two different epitopes of the same antigen. Multispecific antibodies can also be used to localize cytotoxic agents to cells expressing the antigen.
[0416] Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs of different specificities (see Milstein, C. and Cuello, AC, Nature 305 (1983) 537-540, WO 93 / 08829, and Traunecker, A. et al., EMBO J. 10 (1991) 3655-3659) and “knob-in-hole” engineering (see, e.g., US 5,731,168). Multispecific antibodies can also be prepared by the following methods: engineering electrostatic manipulation effects to prepare antibody Fc-heterodimer molecules (WO 2009 / 089004); cross-linking two or more antibodies or fragments (see, for example, US 4,676,980, and Brennan, M. et al., Science 229 (1985) 81-83); using leucine zippers to produce bispecific antibodies (see, for example, Kostelny, SA et al., J. Immunol. 148 (1992) 1547-1553); using specific technology to prepare bispecific antibody fragments (see, for example, Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448); using single-chain Fv (scFv) dimers (Gruber, M. et al., J. Immunol. 152 (1994) 5368-5374); and preparing trispecific antibodies as described in Tutt, A. et al., J. Immunol. 147 (1991) 60-69.
[0417] The antibody or fragment may also be a multispecific antibody as described in WO 2009 / 080251, WO 2009 / 080252, WO 2009 / 080253, WO 2009 / 080254, WO 2010 / 112193, WO 2010 / 115589, WO 2010 / 136172, WO 2010 / 145792 or WO 2010 / 145793.
[0418] The antibody or fragment thereof may also be a multispecific antibody as disclosed in WO 2012 / 163520.
[0419] Bispecific antibodies are generally antibody molecules that specifically bind to two different, non-overlapping epitopes on the same antigen or to two epitopes on different antigens.
[0420] The term "non-overlapping" in this context means that the amino acid residues comprised in the first paratope of the bispecific Fab are not comprised in the second paratope, and the amino acids comprised in the second paratope of the bispecific Fab are not comprised in the first paratope.
[0421] "Knob-in-hole" dimerization modules and their use in antibody engineering are described in Carter P., Ridgway JBB, Presta LG: Immunotechnology, Vol. 2, No. 1, February 1996, pp. 73-73(1).
[0422] The CH3 domain in the antibody heavy chain can be altered by the "knob-into-holes" technique, which is described in detail with several examples in, for example, WO 96 / 027011, Ridgway, JB et al., Protein Eng. 9 (1996) 617-621 and Merchant, AM et al., Nat. Biotechnol. 16 (1998) 677-681. In this method, the interaction surfaces of the two CH3 domains are altered to increase the heterodimerization of the two CH3 domains, thereby increasing the heterodimerization of the polypeptides containing them. One of the two CH3 domains (of the two heavy chains) can be a "knob" and the other a "hole". The introduction of disulfide bridges further stabilizes the heterodimers (Merchant, AM et al., Nature Biotech. 16 (1998) 677-681; Atwell, S. et al., J. Mol. Biol. 270 (1997) 26-35) and increases the yield.
[0423] The mutation T366W in the CH3 domain (of the antibody heavy chain) is denoted as a "knob mutation" or "mutated knob", while the mutations T366S, L368A, Y407V in the CH3 domain (of the antibody heavy chain) are denoted as "hole mutations" or "mutated hole" (numbering according to the Kabat EU index). Additional interchain disulfide bridges located between the CH3 domains can also be used by introducing the S354C mutation into the CH3 domain of the heavy chain with a "knob mutation" (denoted as "knob-cys-mutation" or "mutated knob-cys") or by introducing the Y349C mutation into the CH3 domain of the heavy chain with a "hole mutation" (denoted as "hole-cys-mutation" or "mutated hole-cys") (numbering according to the Kabat EU index) (Merchant, AM et al., Nature Biotech. 16 (1998) 677-681).
[0424] As used herein, the term "domain crossing" means that in an antibody heavy chain VH-CH1 fragment and its corresponding cognate antibody light chain pair, i.e. in antibody Fab (fragment antigen binding), the domain sequence deviates from the native antibody sequence in that at least one heavy chain domain is replaced by its corresponding light chain domain, or vice versa. There are three general types of domain crossings: (i) crossings of CH1 and CL domains, which results from domain crossings in the light chain to a VL-CH1 domain sequence and from domain crossings in the heavy chain fragment to a VH-CL domain sequence (or a full-length antibody heavy chain having a VH-CL-hinge-CH2-CH3 domain sequence); (ii) domain crossings of VH and VL domains, which results from domain crossings in the light chain to a VH-CL domain sequence and from domain crossings in the heavy chain fragment to a VL-CH1 domain sequence; and (iii) domain crossings of a complete light chain (VL-CL) and a complete VH-CH1 heavy chain fragment ("Fab crossings"), which results from domain crossings to a light chain having a VH-CH1 domain sequence and from domain crossings to a heavy chain fragment having a VL-CL domain sequence (all of the above domain sequences are presented in the N-terminal to C-terminal direction).
[0425] As used herein, the term "replacement of one another" with respect to the corresponding heavy chain domain and light chain domain refers to the aforementioned domain intersection. Thus, when the CH1 domain and the CL domain "replacement of one another", it refers to the domain intersection mentioned under item (i) and the resulting heavy chain and light chain domain sequences. Thus, when VH and VL "replacement of one another", it refers to the domain intersection mentioned in item (ii); and when the CH1 and CL domains "replacement of one another" and the VH and VL domains "replacement of one another", it refers to the domain intersection mentioned in item (iii). For example, bispecific antibodies comprising domain intersections are reported in WO 2009 / 080251, WO 2009 / 080252, WO 2009 / 080253, WO 2009 / 080254 and Schaefer, W. et al., Proc. Natl. Acad. Sci USA 108 (2011) 11187-11192. Such antibodies are often referred to as CrossMab.
[0426] In one embodiment, the multispecific antibody further comprises at least one Fab fragment, which includes a domain intersection of CH1 and CL domains as described in item (i) above, or a domain intersection of VH and VL domains as described in item (ii), or a domain intersection of VH-CH1 and VL-VL domains as described in item (iii) above. In the case of a multispecific antibody with domain intersection, Fabs that specifically bind to the same antigen are constructed to have the same domain sequence. Therefore, in the case of a multispecific antibody containing multiple Fabs with domain intersection, the Fabs specifically bind to the same antigen.
[0427] A "humanized" antibody refers to an antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will substantially comprise at least one variable domain, typically two variable domains, wherein all or substantially all HVRs (e.g., CDRs) correspond to HVRs of non-human antibodies, and all or substantially all FRs correspond to FRs of human antibodies. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. An antibody in "humanized form," e.g., a non-human antibody, refers to an antibody that has been humanized.
[0428] As used herein, the term "recombinant antibody" refers to all antibodies (chimeric, humanized and human antibodies) prepared, expressed, created or isolated by recombinant means, such as recombinant cells. This includes antibodies isolated from recombinant cells (such as NS0, HEK, BHK or CHO cells).
[0429] As used herein, the term "antibody fragment" refers to a molecule other than an intact antibody, which includes a portion of an intact antibody and binds to an antigen to which the intact antibody binds, i.e., it is a functional fragment. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2, bispecific antibodies, diabodies, linear antibodies, single-chain antibody molecules (e.g., scFv or scFab).
[0430] II. Compositions and Methods
[0431] Generally speaking, for the recombinant large-scale production of a polypeptide of interest (such as a therapeutic polypeptide), cells that stably express and secrete the polypeptide are required. Such cells are referred to as "recombinant cells" or "recombinant production cells", and the process for producing such cells is referred to as "cell line development". In the first step of the cell line development process, a suitable host cell (such as a CHO cell) is transfected with a nucleic acid sequence suitable for expressing the polypeptide of interest. In a second step, cells that stably express the polypeptide of interest are selected based on the co-expression of a selectable marker that has been co-transfected with a nucleic acid encoding the polypeptide of interest.
[0432] The nucleic acid encoding the polypeptide (i.e., the coding sequence) is called a structural gene. This structural gene is a simple message, and its expression requires additional regulatory elements. Therefore, the structural gene is usually integrated into an expression cassette. The minimum regulatory elements required for the expression cassette to work in mammalian cells are a promoter that works in the mammalian cell, which is located upstream of the structural gene, i.e., 5', and a polyadenylation signal sequence that works in the mammalian cell, which is located downstream of the structural gene, i.e., 3'. The promoter, structural gene, and polyadenylation signal sequence are arranged in an operably linked form.
[0433] In the case where the polypeptide of interest is a heteromultimeric polypeptide composed of different (monomer) polypeptides, not only a single expression cassette is required, but multiple expression cassettes that differ in the structural genes contained, that is, at least one expression cassette is required for each of the different (monomer) polypeptides of the heteromultimeric polypeptide. For example, a full-length antibody is a heteromultimeric polypeptide comprising two copies of a light chain and two copies of a heavy chain. Therefore, a full-length antibody is composed of two different polypeptides. Therefore, the expression of a full-length antibody requires two expression cassettes, one for the light chain and the other for the heavy chain. For example, if the full-length antibody is a bispecific antibody, that is, the antibody comprises two different binding sites that specifically bind to two different antigens, then the light chain and the heavy chain are also different from each other. Therefore, this bispecific full-length antibody is composed of four different polypeptides and requires four expression cassettes.
[0434] The expression cassette for the polypeptide of interest is then incorporated into a so-called "expression vector". An "expression vector" is a nucleic acid that provides all the necessary elements for amplifying the vector in bacterial cells and expressing the contained structural genes in mammalian cells. Typically, an expression vector comprises a prokaryotic plasmid propagation unit, such as a prokaryotic plasmid propagation unit for E. coli, which comprises an origin of replication and a prokaryotic selection marker, as well as a eukaryotic selection marker, and an expression cassette required for expressing the structural gene of interest. An "expression vector" is a transport vehicle for introducing an expression cassette into a mammalian cell.
[0435] As outlined in the previous paragraph, the more complex the polypeptide to be expressed, the higher the number of different expression cassettes required. Inherently, as the number of expression cassettes increases, the size of the nucleic acid integrated into the host cell genome also increases. The size of the expression vector also increases accordingly. However, the actual upper limit of the vector size is within the range of about 15kbp, beyond which the processing and processing efficiency decreases significantly. This problem can be solved by using two or more expression vectors. Therefore, the expression cassette can be split between different expression vectors, each of which contains only some of the expression cassettes.
[0436] Conventional cell line development (CLD) relies on random integration (RI) of vectors carrying the expression cassette for the polypeptide of interest (SOI). Generally speaking, if the vectors are transfected by a random method, several vectors or fragments thereof are integrated into the genome of the cell. Therefore, the RI-based transfection process is unpredictable.
[0437] Therefore, by solving the size problem when splitting the expression cassette between different expression vectors, a new problem arises, which is the random number of integrated expression cassettes and their spatial distribution.
[0438] Generally speaking, the more the expression cassette that is used to express the structural gene is integrated into the genome of the cell, the higher the amount of the polypeptide expressed accordingly becomes.Except the quantity of the expression cassette integrated, the site and locus of integration also have an impact on expression output.For example, if the expression cassette is integrated in the site with low transcriptional activity in the cell genome, only a small amount of coded polypeptide is expressed.But, if the same expression cassette is integrated in the site with high transcriptional activity in the cell genome, a large amount of coded polypeptide is expressed.
[0439] This difference in expression will not cause a problem as long as the expression cassettes for the different polypeptides of the heterologous multimeric polypeptide are all integrated at the same frequency at a locus with comparable transcriptional activity. In this case, all polypeptides of the multimeric polypeptide are expressed in the same amount and the multimeric polypeptide will be assembled correctly.
[0440] However, this situation is unlikely to occur and cannot be guaranteed for molecules consisting of more than two polypeptides. For example, it has been disclosed in WO 2018 / 162517 that high variations in expression yield and product quality were observed using RI, depending on i) the expression cassette sequence and ii) the distribution of the expression cassette between different expression vectors. Without being bound by this theory, this observation is due to the fact that different expression cassettes from different expression vectors integrate at different loci in the cell at different frequencies, resulting in differential expression of different polypeptides of the heteromultimeric polypeptide, i.e., expression at inappropriately different ratios. As a result, some monomeric polypeptides are present in higher amounts, while others are present in lower amounts. This imbalance between the monomers of the heteromultimeric polypeptide leads to incomplete assembly, misassembly, and a slowed secretion rate. All of the aforementioned situations will result in a lower expression yield of the correctly folded heteromultimeric polypeptide and a higher proportion of product-related byproducts.
[0441] Unlike conventional RI CLD, targeted integration (TI) CLD introduces a transgene comprising different expression cassettes at a predetermined "hotspot" in the cell genome. Moreover, the introduction uses a defined ratio of expression cassettes. Therefore, without being bound by this theory, all different polypeptides of the heteromultimeric polypeptide are expressed at the same (or at least comparable and only slightly different) rate and appropriate ratio. As a result, the amount of correctly assembled heteromultimeric polypeptides should be increased and the proportion of product-related byproducts should be reduced.
[0442] In addition, given the limited copy number and the limited integration site, recombinant cells obtained by TI should have better stability than those obtained by RI. In addition, since the selectable marker is only used to select cells with appropriate TI and not for cells with high levels of transgene expression, less mutagenic markers can be used to minimize the possibility of generating sequence variants (SVs) that are partly due to the mutagenicity of selective agents such as methotrexate (MTX) or methionine sulfoximine (MSX).
[0443] However, it has now been found that the sequence of the expression cassette in the transgene used in TI (ie, the expression cassette organization) has a profound effect on the expression of trivalent antibodies (eg, TCB).
[0444] The present invention uses a specific expression cassette organization format with a defined number and sequence of individual expression cassettes. This results in high expression yields and good product quality of trivalent antibodies (eg, TCB) expressed in mammalian cells.
[0445] In order to determine the integration of the transgene with the expression cassette sequence according to the invention, the TI method was used. The present invention provides a novel method for producing recombinant mammalian cells expressing trivalent antibodies (e.g., TCB) using a dual-plasmid recombinase-mediated cassette exchange (RMCE) reaction. The improvement lies in the defined integration at the same locus in a defined sequence, and the resulting high expression of trivalent antibodies (e.g., TCB) and reduced formation of product-related byproducts.
[0446] The presently disclosed subject matter not only provides methods for producing recombinant mammalian cells for stable large-scale production of trivalent antibodies (e.g., TCB), but also provides recombinant mammalian cells having high production of trivalent antibodies (e.g., TCB) with a favorable by-product profile.
[0447] The two-plasmid RMCE strategy used here allows the insertion of multiple expression cassettes into the same TI locus.
[0448] II.a Transgenes and methods according to the invention
[0449] Recombinant mammalian cells expressing trivalent antibodies (e.g., TCB) are reported herein. Trivalent antibodies (e.g., TCB) are heteromultimeric polypeptides that are not naturally expressed by the mammalian cells. More specifically, trivalent antibodies (e.g., TCB) are heterodimeric proteins composed of four polypeptides: a first and a second light chain and a first and a second heavy chain. In order to achieve expression of trivalent antibodies (e.g., TCB), a recombinant nucleic acid containing multiple different expression cassettes in a specific and defined sequence has been integrated into the genome of a mammalian cell.
[0450] Also reported herein are methods for producing recombinant mammalian cells expressing trivalent antibodies (eg, TCBs), and methods for producing trivalent antibodies (eg, TCBs) using said recombinant mammalian cells.
[0451] The present invention is based at least in part on the discovery that the sequences of the different expression cassettes required for the expression of heteromultimeric trivalent antibodies (eg, TCB) (ie, the expression cassette organization) affect the expression yield of the trivalent antibodies (eg, TCB) when integrated into the genome of mammalian cells.
[0452] The present invention is based at least in part on the discovery that dual recombinase-mediated cassette exchange (RMCE) can be used to generate recombinant mammalian cells, such as recombinant CHO cells, in which a defined and specific expression cassette sequence has been integrated into the genome, which in turn leads to efficient expression and production of trivalent antibodies (e.g., TCBs). The integration is achieved by targeted integration at a specific site in the mammalian cell genome. Thus, it is possible to control the expression ratio of different polypeptides of a heteromultimeric polypeptide relative to each other. Thus, efficient expression, correct assembly and successful secretion of correctly folded and assembled trivalent antibodies (e.g., TCBs) are achieved with high expression yields.
[0453] Since a trivalent antibody (e.g., TCB) is a heterogeneous 4-mer, its expression requires at least four different expression cassettes: the first one is used to express the first light chain, the second one is used to express the second light chain, the third one is used to express the first heavy chain, and the fourth one is used to express the second heavy chain. In addition, one or more other expression cassettes for positive selection markers may be included.
[0454] In one example, to examine the effect of expression cassette organization on TI host productivity, RMCE libraries were generated by transfecting two plasmids (front vector and back vector), including different numbers and organizations of individual chains of trivalent antibodies in TCB format. After selection, recovery and verification of RMCE by flow cytometry, the productivity of the library was evaluated in a 14-day batch feed production trial. For specific vector organization, an increase in titer was observed compared to the reference library.
[0455] The effect of antibody chain expression cassette organization on the expression of five different TCBs was evaluated. TCBs 1 to 5 all have different targeting specificities. TCB 3 was tested with 4 different anti-CD3 binding sites.
[0456] For TCB-1, the following results have been obtained; the reference tissue is shaded grey, k = heavy chain with knob mutation; h = heavy chain with hole mutation; l = light chain; xl = light chain with domain swap:
[0457]
[0458] MP = main product, eff.Titer = effective titer = titer times % main product
[0459] The present invention is summarized as follows.
[0460] According to an independent aspect of the present invention is a method for producing a trivalent antibody, the method comprising the following steps:
[0461] a) culturing mammalian cells containing deoxyribonucleic acid encoding the trivalent antibody, and
[0462] b) recovering the trivalent antibody from the cells or culture medium,
[0463] wherein the deoxyribonucleic acid encoding the trivalent antibody is stably integrated into the genome of the mammalian cell and comprises in the 5' to 3' direction (1)
[0465] - a first expression cassette encoding a first heavy chain,
[0466] - a second expression cassette encoding a first light chain,
[0467] - a third expression cassette encoding the first light chain,
[0468] - a fourth expression cassette encoding a second heavy chain, and
[0469] - a fifth expression cassette encoding the second light chain,
[0470] or (2)
[0471] - a first expression cassette encoding a first heavy chain,
[0472] - a second expression cassette encoding a first light chain,
[0473] - a third expression cassette encoding the first light chain,
[0474] - a fourth expression cassette encoding the second heavy chain,
[0475] - a fifth expression cassette encoding the second light chain,
[0476] - a sixth expression cassette encoding the second light chain,
[0477] or (3)
[0478] - a first expression cassette encoding a first heavy chain,
[0479] - a second expression cassette encoding a second heavy chain,
[0480] - a third expression cassette encoding the first light chain,
[0481] - a fourth expression cassette encoding the second light chain,
[0482] - a fifth expression cassette encoding the second light chain,
[0483] or (4)
[0484] - a first expression cassette encoding a first heavy chain,
[0485] - a second expression cassette encoding a second heavy chain,
[0486] - a third expression cassette encoding the first light chain,
[0487] - a fourth expression cassette encoding the second light chain,
[0488] - a fifth expression cassette encoding the first heavy chain,
[0489] - a sixth expression cassette encoding the second light chain,
[0490] or (5)
[0491] - a first expression cassette encoding a first heavy chain,
[0492] - a second expression cassette encoding a second heavy chain,
[0493] - a third expression cassette encoding the first light chain,
[0494] - a fourth expression cassette encoding the second light chain,
[0495] - a fifth expression cassette encoding the second heavy chain,
[0496] - a sixth expression cassette encoding the second light chain,
[0497] - a seventh expression cassette encoding the second light chain,
[0498] or (6)
[0499] - a first expression cassette encoding a first light chain,
[0500] - a second expression cassette encoding a first light chain,
[0501] - a third expression cassette encoding the first heavy chain,
[0502] - a fourth expression cassette encoding the second heavy chain,
[0503] - a fifth expression cassette encoding the second light chain,
[0504] - a sixth expression cassette encoding the second light chain.
[0505] The trivalent antibody encoding deoxyribonucleic acid can be stably integrated into the genome of mammalian cells by any method known to those skilled in the art, as long as the specific expression cassette sequence is maintained.
[0506] An independent aspect of the present invention is a deoxyribonucleic acid encoding a trivalent antibody comprising in the 5' to 3' direction (1)
[0508] - a first expression cassette encoding a first heavy chain,
[0509] - a second expression cassette encoding a first light chain,
[0510] - a third expression cassette encoding the first light chain,
[0511] - a fourth expression cassette encoding a second heavy chain, and
[0512] - a fifth expression cassette encoding the second light chain,
[0513] or (2)
[0514] - a first expression cassette encoding a first heavy chain,
[0515] - a second expression cassette encoding a first light chain,
[0516] - a third expression cassette encoding the first light chain,
[0517] - a fourth expression cassette encoding the second heavy chain,
[0518] - a fifth expression cassette encoding the second light chain,
[0519] - a sixth expression cassette encoding the second light chain,
[0520] or (3)
[0521] - a first expression cassette encoding a first heavy chain,
[0522] - a second expression cassette encoding a second heavy chain,
[0523] - a third expression cassette encoding the first light chain,
[0524] - a fourth expression cassette encoding the second light chain,
[0525] - a fifth expression cassette encoding the second light chain,
[0526] or (4)
[0527] - a first expression cassette encoding a first heavy chain,
[0528] - a second expression cassette encoding a second heavy chain,
[0529] - a third expression cassette encoding the first light chain,
[0530] - a fourth expression cassette encoding the second light chain,
[0531] - a fifth expression cassette encoding the first heavy chain,
[0532] - a sixth expression cassette encoding the second light chain,
[0533] or (5)
[0534] - a first expression cassette encoding a first heavy chain,
[0535] - a second expression cassette encoding a second heavy chain,
[0536] - a third expression cassette encoding the first light chain,
[0537] - a fourth expression cassette encoding the second light chain,
[0538] - a fifth expression cassette encoding the second heavy chain,
[0539] - a sixth expression cassette encoding the second light chain,
[0540] - a seventh expression cassette encoding the second light chain,
[0541] or (6)
[0542] - a first expression cassette encoding a first light chain,
[0543] - a second expression cassette encoding a first light chain,
[0544] - a third expression cassette encoding the first heavy chain,
[0545] - a fourth expression cassette encoding the second heavy chain,
[0546] - a fifth expression cassette encoding the second light chain,
[0547] - a sixth expression cassette encoding the second light chain.
[0548] An independent aspect of the present invention is the use of a deoxyribonucleic acid comprising in the 5' to 3' direction: (1)
[0550] - a first expression cassette encoding a first heavy chain,
[0551] - a second expression cassette encoding a first light chain,
[0552] - a third expression cassette encoding the first light chain,
[0553] - a fourth expression cassette encoding a second heavy chain, and
[0554] - a fifth expression cassette encoding the second light chain,
[0555] or (2)
[0556] - a first expression cassette encoding a first heavy chain,
[0557] - a second expression cassette encoding a first light chain,
[0558] - a third expression cassette encoding the first light chain,
[0559] - a fourth expression cassette encoding the second heavy chain,
[0560] - a fifth expression cassette encoding the second light chain,
[0561] - a sixth expression cassette encoding the second light chain,
[0562] or (3)
[0563] - a first expression cassette encoding a first heavy chain,
[0564] - a second expression cassette encoding a second heavy chain,
[0565] - a third expression cassette encoding the first light chain,
[0566] - a fourth expression cassette encoding the second light chain,
[0567] - a fifth expression cassette encoding the second light chain,
[0568] or (4)
[0569] - a first expression cassette encoding a first heavy chain,
[0570] - a second expression cassette encoding a second heavy chain,
[0571] - a third expression cassette encoding the first light chain,
[0572] - a fourth expression cassette encoding the second light chain,
[0573] - a fifth expression cassette encoding the first heavy chain,
[0574] - a sixth expression cassette encoding the second light chain,
[0575] or (5)
[0576] - a first expression cassette encoding a first heavy chain,
[0577] - a second expression cassette encoding a second heavy chain,
[0578] - a third expression cassette encoding the first light chain,
[0579] - a fourth expression cassette encoding the second light chain,
[0580] - a fifth expression cassette encoding the second heavy chain,
[0581] - a sixth expression cassette encoding the second light chain,
[0582] - a seventh expression cassette encoding the second light chain,
[0583] or (6)
[0584] - a first expression cassette encoding a first light chain,
[0585] - a second expression cassette encoding a first light chain,
[0586] - a third expression cassette encoding the first heavy chain,
[0587] - a fourth expression cassette encoding the second heavy chain,
[0588] - a fifth expression cassette encoding the second light chain,
[0589] - a sixth expression cassette encoding the second light chain.
[0590] An independent aspect of the invention is a recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent antibody integrated into the genome of the cell,
[0591] The deoxyribonucleic acid encoding the trivalent antibody comprises in the 5' to 3' direction (1)
[0593] - a first expression cassette encoding a first heavy chain,
[0594] - a second expression cassette encoding a first light chain,
[0595] - a third expression cassette encoding the first light chain,
[0596] - a fourth expression cassette encoding a second heavy chain, and
[0597] - a fifth expression cassette encoding the second light chain,
[0598] or (2)
[0599] - a first expression cassette encoding a first heavy chain,
[0600] - a second expression cassette encoding a first light chain,
[0601] - a third expression cassette encoding the first light chain,
[0602] - a fourth expression cassette encoding the second heavy chain,
[0603] - a fifth expression cassette encoding the second light chain,
[0604] - a sixth expression cassette encoding the second light chain,
[0605] or (3)
[0606] - a first expression cassette encoding a first heavy chain,
[0607] - a second expression cassette encoding a second heavy chain,
[0608] - a third expression cassette encoding the first light chain,
[0609] - a fourth expression cassette encoding the second light chain,
[0610] - a fifth expression cassette encoding the second light chain,
[0611] or (4)
[0612] - a first expression cassette encoding a first heavy chain,
[0613] - a second expression cassette encoding a second heavy chain,
[0614] - a third expression cassette encoding the first light chain,
[0615] - a fourth expression cassette encoding the second light chain,
[0616] - a fifth expression cassette encoding the first heavy chain,
[0617] - a sixth expression cassette encoding the second light chain,
[0618] or (5)
[0619] - a first expression cassette encoding a first heavy chain,
[0620] - a second expression cassette encoding a second heavy chain,
[0621] - a third expression cassette encoding the first light chain,
[0622] - a fourth expression cassette encoding the second light chain,
[0623] - a fifth expression cassette encoding the second heavy chain,
[0624] - a sixth expression cassette encoding the second light chain,
[0625] - a seventh expression cassette encoding the second light chain,
[0626] or (6)
[0627] - a first expression cassette encoding a first light chain,
[0628] - a second expression cassette encoding a first light chain,
[0629] - a third expression cassette encoding the first heavy chain,
[0630] - a fourth expression cassette encoding the second heavy chain,
[0631] - a fifth expression cassette encoding the second light chain,
[0632] - a sixth expression cassette encoding the second light chain.
[0633] An independent aspect of the present invention is a composition comprising two DNAs, which in turn comprise three different recombination recognition sequences and five to seven expression cassettes, wherein
[0634] - the first deoxyribonucleic acid comprises in the 5' to 3' direction (1)
[0636] - a first recombination recognition sequence,
[0637] - a first expression cassette encoding a first heavy chain,
[0638] - a second expression cassette encoding a first light chain,
[0639] - a third expression cassette encoding the first light chain, and
[0640] - a first copy of the third recombination recognition sequence,
[0641] or (2)
[0642] - a first recombination recognition sequence,
[0643] - a first expression cassette encoding a first heavy chain,
[0644] - a second expression cassette encoding a first light chain,
[0645] - a third expression cassette encoding the first light chain, and
[0646] - a first copy of the third recombination recognition sequence,
[0647] or (3)
[0648] - a first recombination recognition sequence,
[0649] - a first expression cassette encoding a first heavy chain,
[0650] - a second expression cassette encoding a second heavy chain,
[0651] - a third expression cassette encoding the first light chain,
[0652] - a fourth expression cassette encoding a second light chain, and
[0653] - a first copy of the third recombination recognition sequence,
[0654] or (4)
[0655] - a first recombination recognition sequence,
[0656] - a first expression cassette encoding a first heavy chain,
[0657] - a second expression cassette encoding a second heavy chain,
[0658] - a third expression cassette encoding the first light chain,
[0659] - a fourth expression cassette encoding a second light chain, and
[0660] - a first copy of the third recombination recognition sequence,
[0661] or (5)
[0662] - a first recombination recognition sequence,
[0663] - a first expression cassette encoding a first heavy chain,
[0664] - a second expression cassette encoding a second heavy chain,
[0665] - a third expression cassette encoding the first light chain,
[0666] - a fourth expression cassette encoding a second light chain, and
[0667] - a first copy of the third recombination recognition sequence,
[0668] or (6)
[0669] - a first recombination recognition sequence,
[0670] - a first expression cassette encoding a first light chain,
[0671] - a second expression cassette encoding a first light chain,
[0672] - a third expression cassette encoding the first heavy chain, and
[0673] - a first copy of the third recombination recognition sequence,
[0674] and
[0675] - The second deoxyribonucleic acid comprises (1) in the 5' to 3' direction
[0676] - a second copy of the third recombination recognition sequence,
[0677] - a fourth expression cassette encoding the second heavy chain,
[0678] - a fifth expression cassette encoding a second light chain, and
[0679] - a second recombination recognition sequence,
[0680] or (2)
[0681] - a second copy of the third recombination recognition sequence,
[0682] - a fourth expression cassette encoding the second heavy chain,
[0683] - a fifth expression cassette encoding the second light chain,
[0684] - a sixth expression cassette encoding the second light chain, and
[0685] - a second recombination recognition sequence,
[0686] or (3)
[0687] - a second copy of the third recombination recognition sequence,
[0688] - a fifth expression cassette encoding a second light chain, and
[0689] - a second recombination recognition sequence,
[0690] or (4)
[0691] - a second copy of the third recombination recognition sequence,
[0692] - a fifth expression cassette encoding the first heavy chain,
[0693] - a sixth expression cassette encoding the second light chain, and
[0694] - a second recombination recognition sequence,
[0695] or (5)
[0696] - a second copy of the third recombination recognition sequence,
[0697] - a fifth expression cassette encoding the second heavy chain,
[0698] - a sixth expression cassette encoding the second light chain,
[0699] - a seventh expression cassette encoding the second light chain, and
[0700] - a second recombination recognition sequence,
[0701] or (6)
[0702] - a second copy of the third recombination recognition sequence,
[0703] - a fourth expression cassette encoding the second heavy chain,
[0704] - a fifth expression cassette encoding the second light chain,
[0705] - a sixth expression cassette encoding the second light chain, and
[0706] - a second recombination recognition sequence.
[0707] In one embodiment, the first and second deoxyribonucleic acids both contain the tissue according to (1); or the first and second deoxyribonucleic acids both contain the tissue according to (2); or the first and second deoxyribonucleic acids both contain the tissue according to (3); or the first and second deoxyribonucleic acids both contain the tissue according to (4); or the first and second deoxyribonucleic acids both contain the tissue according to (5); or the first and second deoxyribonucleic acids both contain the tissue according to (6).
[0708] An independent aspect of the invention is a method for producing a recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent antibody and secreting a trivalent antibody, the method comprising the steps of:
[0709] a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of the mammalian cell, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence flanked by at least one first selection marker, and a third recombination recognition sequence located between the first recombination recognition sequence and the second recombination recognition sequence, and all of the recombination recognition sequences are different;
[0710] b) introducing into the cell provided in a) a composition of two deoxyribonucleic acids, said two deoxyribonucleic acids comprising three different recombination recognition sequences and five to seven expression cassettes, wherein
[0711] - the first deoxyribonucleic acid comprises in the 5' to 3' direction (1)
[0713] - a first recombination recognition sequence,
[0714] - a first expression cassette encoding a first heavy chain,
[0715] - a second expression cassette encoding a first light chain,
[0716] - a third expression cassette encoding the first light chain, and
[0717] - a first copy of the third recombination recognition sequence,
[0718] or (2)
[0719] - a first recombination recognition sequence,
[0720] - a first expression cassette encoding a first heavy chain,
[0721] - a second expression cassette encoding a first light chain,
[0722] - a third expression cassette encoding the first light chain, and
[0723] - a first copy of the third recombination recognition sequence,
[0724] or (3)
[0725] - a first recombination recognition sequence,
[0726] - a first expression cassette encoding a first heavy chain,
[0727] - a second expression cassette encoding a second heavy chain,
[0728] - a third expression cassette encoding the first light chain,
[0729] - a fourth expression cassette encoding a second light chain, and
[0730] - a first copy of the third recombination recognition sequence,
[0731] or (4)
[0732] - a first recombination recognition sequence,
[0733] - a first expression cassette encoding a first heavy chain,
[0734] - a second expression cassette encoding a second heavy chain,
[0735] - a third expression cassette encoding the first light chain,
[0736] - a fourth expression cassette encoding a second light chain, and
[0737] - a first copy of the third recombination recognition sequence,
[0738] or (5)
[0739] - a first recombination recognition sequence,
[0740] - a first expression cassette encoding a first heavy chain,
[0741] - a second expression cassette encoding a second heavy chain,
[0742] - a third expression cassette encoding the first light chain,
[0743] - a fourth expression cassette encoding a second light chain, and
[0744] - a first copy of the third recombination recognition sequence,
[0745] or (6)
[0746] - a first recombination recognition sequence,
[0747] - a first expression cassette encoding a first light chain,
[0748] - a second expression cassette encoding a first light chain,
[0749] - a third expression cassette encoding the first heavy chain, and
[0750] - a first copy of a third recombination recognition sequence, and
[0751] - The second deoxyribonucleic acid comprises (1) in the 5' to 3' direction
[0752] - a second copy of the third recombination recognition sequence,
[0753] - a fourth expression cassette encoding the second heavy chain,
[0754] - a fifth expression cassette encoding a second light chain, and
[0755] - a second recombination recognition sequence,
[0756] or (2)
[0757] - a second copy of the third recombination recognition sequence,
[0758] - a fourth expression cassette encoding the second heavy chain,
[0759] - a fifth expression cassette encoding the second light chain,
[0760] - a sixth expression cassette encoding the second light chain, and
[0761] - a second recombination recognition sequence,
[0762] or (3)
[0763] - a second copy of the third recombination recognition sequence,
[0764] - a fifth expression cassette encoding a second light chain, and
[0765] - a second recombination recognition sequence,
[0766] or (4)
[0767] - a second copy of the third recombination recognition sequence,
[0768] - a fifth expression cassette encoding the first heavy chain,
[0769] - a sixth expression cassette encoding the second light chain, and
[0770] - a second recombination recognition sequence,
[0771] or (5)
[0772] - a second copy of the third recombination recognition sequence,
[0773] - a fifth expression cassette encoding the second heavy chain,
[0774] - a sixth expression cassette encoding the second light chain,
[0775] - a seventh expression cassette encoding the second light chain, and
[0776] - a second recombination recognition sequence,
[0777] or (6)
[0778] - a second copy of the third recombination recognition sequence,
[0779] - a fourth expression cassette encoding the second heavy chain,
[0780] - a fifth expression cassette encoding the second light chain,
[0781] - a sixth expression cassette encoding the second light chain, and
[0782] - a second recombination recognition sequence,
[0783] wherein the first recombinant DNA and the second DNA
[0784] The first recombination recognition sequence to the third recombination recognition sequence matches the first recombination recognition sequence to the third recombination recognition sequence on the integrated exogenous nucleotide sequence,
[0785] The 5' terminal portion and the 3' terminal portion of the expression cassette encoding a second selection marker are
[0786] when taken together form a functional expression cassette for said one second selection marker;
[0787] c)
[0788] i) is introduced simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b);
[0789] or
[0790] ii) Then introduce
[0791] one or more recombinases,
[0792] wherein the one or more recombinases recognize the recombination recognition sequences of the first deoxyribonucleic acid and the second deoxyribonucleic acid; (and optionally wherein the one or more recombinases perform two recombinase-mediated cassette exchanges;)
[0793] as well as
[0794] d) selecting cells expressing said second selection marker and secreting said trivalent antibody,
[0795] Thereby, a recombinant mammalian cell is produced which contains the deoxyribonucleic acid encoding the trivalent antibody and secretes the trivalent antibody.
[0796] In one embodiment, the first and second deoxyribonucleic acids both contain the tissue according to (1); or the first and second deoxyribonucleic acids both contain the tissue according to (2); or the first and second deoxyribonucleic acids both contain the tissue according to (3); or the first and second deoxyribonucleic acids both contain the tissue according to (4); or the first and second deoxyribonucleic acids both contain the tissue according to (5); or the first and second deoxyribonucleic acids both contain the tissue according to (6).
[0797] In one embodiment of all independent aspects and all related embodiments of the invention, the deoxyribonucleic acid encoding the trivalent, bispecific antibody is stably integrated into a single locus in the genome of a mammalian cell by targeted integration.
[0798] In one embodiment of all independent aspects and all related embodiments of the invention, the deoxyribonucleic acid encoding the trivalent, bispecific antibody is stably integrated into a single locus in the genome of a mammalian cell by a single or double recombinase-mediated cassette exchange reaction.
[0799] In a related embodiment of each independent aspect and all relevant embodiments of the invention, the first heavy chain comprises the mutation T366W in the CH3 domain (according to Kabat numbering) and the second heavy chain comprises the mutations T366S, L368A and Y407V in the CH3 domain (according to Kabat numbering), or vice versa.
[0800] In a related embodiment according to each independent aspect and all related embodiments of the invention, one of the heavy chains further comprises the mutation S354C and the respective other heavy chain comprises the mutation Y349C (according to Kabat numbering).
[0801] In a related embodiment according to each independent aspect and all related embodiments of the invention the first heavy chain is an extended heavy chain comprising an additional domain exchanged Fab fragment.
[0802] In a related embodiment according to each independent aspect and all related embodiments of the invention, the first light chain is a domain exchanged light chain VH-VL or CH1-CL.
[0803] In a related embodiment according to each independent aspect and all related embodiments of the present invention
[0804] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0805] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0806] - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and
[0807] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0808] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0809] In a related embodiment according to each independent aspect and all related embodiments of the present invention
[0810] - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a second heavy chain variable domain, a CL domain, a hinge region, a CH2 domain and a CH3 domain,
[0811] - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain,
[0812] - the first light chain comprises, from N-terminus to C-terminus, a first light chain variable domain and a CH1 domain, and
[0813] - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain,
[0814] wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site.
[0815] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the deoxyribonucleic acid is stably integrated into the genome of the mammalian cell at a single site or locus.
[0816] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the deoxyribonucleic acid encoding the trivalent antibody comprises an additional expression cassette encoding a selectable marker.
[0817] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the expression cassette encoding the selection marker is partially located 5' and partially located 3' to the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal, wherein the start codon is operably linked to the coding sequence.
[0818] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the 5' portion of the expression cassette encoding the selection marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is flanked upstream by a third expression cassette and the start codon is flanked downstream by a third recombination recognition sequence; and the 3' portion of the expression cassette encoding the selection marker comprises a nucleic acid encoding the selection marker, which lacks a start codon and is flanked upstream by a third recombination recognition sequence and downstream by a fourth expression cassette, wherein the start codon is operably linked to a coding sequence.
[0819] In a related embodiment according to each independent aspect and all related embodiments of the present invention
[0820] Each expression cassette encoding a selectable marker comprises in the 5' to 3' direction a promoter, the nucleic acid encoding the antibody chain and a polyadenylation signal sequence, and optionally a terminator sequence.
[0821] and
[0822] Each expression cassette encoding a selectable marker comprises, in the 5' to 3' direction, a promoter, nucleic acid encoding the selectable marker and a polyadenylation signal sequence, and optionally a terminator sequence.
[0823] In a related embodiment according to each independent aspect and all related embodiments of the present invention, for the expression cassette other than the selection marker, the promoter is the human CMV promoter with intron A, the polyadenylation signal sequence is the bGH polyadenylation signal sequence, and the terminator is the hGT terminator, for the expression cassette of the selection marker, wherein the promoter is the SV40 promoter, and the polyadenylation signal sequence is the SV40 polyadenylation signal sequence and there is no terminator.
[0824] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the mammalian cell is a CHO cell.
[0825] In a related embodiment according to each independent aspect and all related embodiments of the invention, if the organization in the 5' to 3' direction has as the first expression cassette the expression cassette encoding the first heavy chain, all cassettes are arranged unidirectionally.
[0826] In a related embodiment of each independent aspect and all related embodiments according to the present invention, if the organization along the 5' to 3' direction is a first expression cassette encoding a first light chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a second light chain, then the first to third expression cassettes are arranged unidirectionally, and the fourth to sixth expression cassettes are arranged unidirectionally, whereby the first to third expression cassettes are arranged in the opposite direction of the fourth to sixth expression cassettes.
[0827] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the expression cassette encoding the selection marker is partially located 5' and partially located 3' of the third recombination recognition sequence, wherein the 5' part of the expression cassette comprises a promoter and a start codon, and the 3' part of the expression cassette comprises a coding sequence without a start codon and a poly A signal.
[0828] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the 5' portion of the expression cassette encoding the selection marker comprises a promoter sequence operably linked to a start codon, whereby the promoter sequence is flanked upstream by a second expression cassette (i.e., positioned downstream of the second expression cassette), and the start codon is flanked downstream by a third recombination recognition sequence (i.e., positioned upstream of the third recombination recognition sequence); and the 3' portion of the expression cassette encoding the selection marker comprises a nucleic acid encoding a selection marker, which lacks a start codon operably linked to a polyadenylation sequence, and is flanked upstream by a third recombination recognition sequence and downstream by a third expression cassette.
[0829] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the start codon is a translation start codon. In one embodiment, the start codon is ATG.
[0830] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the first deoxyribonucleic acid is integrated into a first vector and the second deoxyribonucleic acid is integrated into a second vector.
[0831] In a related embodiment according to each independent aspect and all related embodiments of the invention, each of the expression cassettes comprises in the 5' to 3' direction a promoter, a coding sequence and a polyadenylation signal sequence, optionally followed by a terminator sequence, all operably linked to each other.
[0832] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the mammalian cell is a CHO cell. In one embodiment, the CHO cell is a CHO-K1 cell.
[0833] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the recombinase recognition sequences are L3, 2L and LoxFas. In one embodiment, L3 has the sequence SEQ ID NO: 01, 2L has the sequence SEQ ID NO: 02, and LoxFas has the sequence SEQ ID NO: 03. In one embodiment, the first recombinase recognition sequence is L3, the second recombinase recognition sequence is 2L, and the third recombinase recognition sequence is LoxFas.
[0834] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH poly A site, and the terminator sequence is a hGT terminator.
[0835] In a related embodiment of each independent aspect and all related embodiments according to the present invention, for the expression cassette other than the selection marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH poly A site, and the terminator sequence is a hGT terminator, for the expression cassette of the selection marker, wherein the promoter is a SV40 promoter, and the polyadenylation signal sequence is a SV40 poly A site and there is no terminator sequence.
[0836] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the human CMV promoter has the sequence of SEQ ID NO: 04. In one embodiment, the human CMV promoter has the sequence of SEQ ID NO:06.
[0837] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the bGH polyadenylation signal sequence is SEQ ID NO:08.
[0838] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the hGT terminator has the sequence of SEQ ID NO:09.
[0839] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the SV40 promoter has the sequence of SEQ ID NO:10.
[0840] In a related embodiment according to each independent aspect and all related embodiments of the present invention, the SV40 polyadenylation signal sequence is SEQ ID NO:07.
[0841] In one embodiment according to all aspects and embodiments of the invention the trivalent antibody is a therapeutic antibody.
[0842] In one embodiment according to all aspects and embodiments of the present invention, a trivalent bispecific (therapeutic) antibody (TCB) comprises
[0843] - a first Fab fragment and a second Fab fragment, wherein each binding site of the first Fab fragment and the second Fab fragment specifically binds to a second antigen,
[0844] - a third Fab fragment, wherein the binding site of the third Fab fragment specifically binds to the first antigen, and wherein the third Fab fragment comprises a domain crossover such that the variable light chain domain (VL) and the variable heavy chain domain (VH) are replaced with each other, and
[0845] - an Fc region comprising a first Fc region polypeptide and a second Fc region polypeptide,
[0846] wherein the first Fab fragment and the second Fab fragment each comprise a heavy chain fragment and a full-length light chain,
[0847] wherein the C-terminus of the heavy chain fragment of the first Fab fragment is fused to the N-terminus of the first Fc region polypeptide,
[0848] The C-terminus of the heavy chain fragment of the second Fab fragment is fused to the N-terminus of the variable light chain domain of the third Fab fragment, and the C-terminus of the heavy chain constant domain 1 of the third Fab fragment is fused to the N-terminus of the second Fc region polypeptide.
[0849] In one embodiment according to all aspects and embodiments of the present invention, the trivalent antibody is an anti-CD3 / CD20 bispecific antibody. In one embodiment, the anti-CD3 / CD20 bispecific antibody is a TCB with CD20 as the second antigen. In one embodiment, the bispecific anti-CD3 / CD20 antibody is RG6026. Such antibodies are reported in WO 2016 / 020309, which is incorporated herein by reference in its entirety.
[0850] In one embodiment according to all aspects and embodiments of the present invention, the trivalent antibody is an anti-CD3 / CEA bispecific antibody. In one embodiment, the anti-CD3 / CEA bispecific antibody is a TCB with CEA as the second antigen. In one embodiment, the bispecific anti-CD3 / CEA antibody is RO6958688 or RG7802 or cibisatamab. Such antibodies are reported in WO 2017 / 055389, which is incorporated herein by reference in its entirety.
[0851] II.b Recombinase-mediated cassette exchange (RMCE)
[0852] Targeted integration allows the exogenous nucleotide sequence to be integrated into a predetermined site of the mammalian cell genome. In certain embodiments, targeted integration is mediated by a recombinase that recognizes one or more recombination recognition sequences (RRS). In certain embodiments, targeted integration is mediated by homologous recombination.
[0853] A "recombination recognition sequence" (RRS) is a nucleotide sequence recognized by a recombinase and is necessary for a recombinase-mediated recombination event and sufficient to initiate such a recombination event. An RRS can be used to define the position in a nucleotide sequence where a recombination event will occur.
[0854] In certain embodiments, the RRS is selected from the group consisting of: LoxP sequence, LoxP L3 sequence, LoxP 2L sequence, LoxFas sequence, Lox511 sequence, Lox2272 sequence, Lox2372 sequence, Lox5171 sequence, Loxm2 sequence, Lox71 sequence, Lox66 sequence, FRT sequence, Bxb1 attP sequence, Bxb1 attB sequence, φC31 attP sequence and φC31 attB sequence. If multiple RRSs must be present, the selection of each of these sequences depends on another sequence within the limit of selecting a different RRS.
[0855] In certain embodiments, the RRS may be recognized by the Cre recombinase. In certain embodiments, the RRS may be recognized by the FLP recombinase. In certain embodiments, the RRS may be recognized by the Bxb1 integrase. In certain embodiments, the RRS may be recognized by the φC31 integrase.
[0856] In certain embodiments, when RRS is a LoxP site, the cell requires Cre recombinase to perform recombination. In certain embodiments, when RRS is a FRT site, the cell requires FLP recombinase to perform recombination. In certain embodiments, when RRS is a Bxb1 attP or Bxb1 attB site, the cell requires Bxb1 integrase to perform recombination. In certain embodiments, when RRS is a φC31 attP or φC31attB site, the cell requires φC31 integrase to perform recombination. The recombinase can be introduced into the cell using an expression vector comprising the coding sequence of the enzyme.
[0857] The Cre-LoxP site-specific recombination system has been widely used in many biological experimental systems. Cre is a 38kDa site-specific DNA recombinase that recognizes a 34bp LoxP sequence. Cre is derived from bacteriophage P1 and belongs to the tyrosine family site-specific recombinase. Cre recombinase can mediate intramolecular and intermolecular recombination between LoxP sequences. The LoxP sequence consists of an 8bp non-palindromic core region and two 13bp inverted repeat sequences flanked by it. The Cre recombinase binds to the 13bp repeat sequence, thereby mediating the recombination within the 8bp core region. Cre-LoxP-mediated recombination occurs with high efficiency and does not require any other host factors. If two LoxP sequences are placed in the same nucleotide sequence in the same orientation, the Cre-mediated recombination will excise the DNA sequence between the two LoxP sequences to form a covalent closed loop. If two LoxP sequences are placed in the same nucleotide sequence in opposite positions, the Cre-mediated recombination will reverse the orientation of the DNA sequence between the two sequences. If the two LoxP sequences are on two different DNA molecules and if one DNA molecule is a circular molecule, Cre-mediated recombination will result in the integration of the circular DNA sequence.
[0858] In certain embodiments, the LoxP sequence is a wild-type LoxP sequence. In certain embodiments, the LoxP sequence is a mutant LoxP sequence. Mutant LoxP sequences have been developed to improve the efficiency of Cre-mediated integration or replacement. In certain embodiments, the mutant LoxP sequence is selected from the group consisting of the following items: LoxP L3 sequence, LoxP 2L sequence, LoxFas sequence, Lox511 sequence, Lox2272 sequence, Lox2372 sequence, Lox5171 sequence, Loxm2 sequence, Lox71 sequence and Lox66 sequence. For example, the Lox71 sequence has 5bp mutations in the 13bp repeat sequence on the left. The Lox66 sequence has 5bp mutations in the 13bp repeat sequence on the right. Both the wild-type LoxP sequence and the mutant LoxP sequence can mediate Cre-dependent recombination.
[0859] The term "matching RRS" means that recombination has occurred between two RRSs. In certain embodiments, the two matching RRSs are identical. In certain embodiments, both RRSs are wild-type LoxP sequences. In certain embodiments, both RRSs are mutant LoxP sequences. In certain embodiments, both RRSs are wild-type FRT sequences. In certain embodiments, both RRSs are mutant FRT sequences. In certain embodiments, the two matching RRSs are different sequences, but can be recognized by the same recombinase. In certain embodiments, the first matching RRS is a Bxb1 attP sequence, and the second matching RRS is a Bxb1 attB sequence. In certain embodiments, the first matching RRS is a φC31 attB sequence, and the second matching RRS is a φC31 attB sequence.
[0860] II.c Exemplary mammalian cells suitable for TI
[0861] Any known or future mammalian cell suitable for TI that contains exogenous nucleic acid ("landing site") as described above can be used in the present invention.
[0862] The present invention is exemplified by CHO cells containing exogenous nucleic acid (landing site) according to the preceding section. This is merely to illustrate the present invention and should not be construed as limiting in any way. The true scope of the present invention is set in the claims.
[0863] In a preferred embodiment, the mammalian cell comprising the exogenous nucleotide sequence integrated at a single site within the genomic locus of the mammalian cell is a CHO cell.
[0864] An exemplary mammalian cell suitable for the present invention comprising an exogenous nucleotide sequence integrated at a single site within the locus of its genome is a CHO cell with a landing site (= an exogenous nucleotide sequence integrated at a single site within the genomic locus of a mammalian cell) comprising three heterologous specific loxP sites for Cre recombinase-mediated DNA recombination. These heterologous specific loxP sites are L3, LoxFas and 2L (see, e.g., Lanza et al., Biotechnol. J. 7 (2012) 898-908; Wong et al., Nucleic Acids Res. 33 (2005) e147), whereby L3 and 2L are flanked by the landing site at the 5' and 3' ends, respectively, and LoxFas is located between the L3 site and the 2L site. The landing site also comprises a bicistronic unit that links the expression of a selectable marker to the expression of a fluorescent GFP protein via an IRES, thereby allowing for the stabilization of the landing site by positive selection, as well as selection for the absence of the site after transfection and Cre recombination (negative selection). Green fluorescent protein (GFP) was used to monitor the RMCE reaction. An exemplary GFP has the sequence of SEQ ID NO:11.
[0865] This configuration of the landing site as outlined in the previous paragraph allows the simultaneous integration of two vectors, the so-called front vector with L3 and LoxFas sites, and the back vector comprising LoxFas and 2L sites. The functional elements of the selectable marker gene, which is different from the selectable marker gene present in the landing site, are distributed between the two vectors: the promoter and the start codon are located on the front vector, while the coding region and the poly A signal are located on the back vector. Only the correct Cre-mediated integration of the nucleic acids from both vectors induces resistance to the corresponding selective agents.
[0866] Generally speaking, mammalian cells suitable for TI are mammalian cells that contain an exogenous nucleotide sequence integrated at a single site within the locus of the mammalian cell genome, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence flanked by at least one first selective marker, and a third recombination recognition sequence located between the first recombination recognition sequence and the second recombination recognition sequence, and all recombination recognition sequences are different. The exogenous nucleotide sequence is called a "landing site".
[0867] The disclosed subject matter of the present invention uses mammalian cells suitable for TI of exogenous nucleotide sequences. In certain embodiments, the mammalian cells suitable for TI contain exogenous nucleotide sequences at an integration site integrated into the genome of the mammalian cell. Such mammalian cells suitable for TI can also be denoted as TI host cells.
[0868] In certain embodiments, the mammalian cells suitable for TI are hamster cells, human cells, rat cells or mouse cells comprising a landing site. In certain embodiments, the mammalian cells suitable for TI are Chinese hamster ovary (CHO) cells, CHO K1 cells, CHO K1SV cells, CHO DG44 cells, CHO DUKXB-11 cells, CHO K1S cells or CHO K1M cells comprising a landing site.
[0869] In certain embodiments, the mammalian cell suitable for TI comprises an integrated exogenous nucleotide sequence, wherein the exogenous nucleotide sequence comprises one or more recombination recognition sequences (RRS). In certain embodiments, the exogenous nucleotide sequence comprises at least two RRS. RRS can be recognized by a recombinase (e.g., Cre recombinase, FLP recombinase, Bxb1 integrase or φC31 integrase). RRS can be selected from the group consisting of: LoxP sequence, LoxP L3 sequence, LoxP 2L sequence, LoxFas sequence, Lox511 sequence, Lox2272 sequence, Lox2372 sequence, Lox5171 sequence, Loxm2 sequence, Lox71 sequence, Lox66 sequence, FRT sequence, Bxb1 attP sequence, Bxb1 attB sequence, φC31 attP sequence and φC31 attB sequence.
[0870] In certain embodiments, the exogenous nucleotide sequence includes the first RRS, the second RRS and the third RRS, and at least one selective marker between the first RRS and the second RRS, and the third RRS is different from the first RRS and / or the second RRS. In certain embodiments, the exogenous nucleotide sequence also includes the second selective marker, and the first selective marker and the second selective marker are different. In certain embodiments, the exogenous nucleotide sequence also includes the third selective marker and an internal ribosome entry site (IRES), wherein IRES is operably connected to the third selective marker. The third selective marker may be different from the first selective marker or the second selective marker.
[0871] The selectable marker can be selected from the group consisting of aminoglycoside phosphotransferase (APH) (e.g., hygromycin phosphotransferase (HYG), neomycin and G418 APH), dihydrofolate reductase (DHFR), thymidine kinase (TK), glutamine synthetase (GS), asparagine synthetase, tryptophan synthetase (indole), histidinol dehydrogenase (histidinol D), and genes encoding resistance to puromycin, blasticidin, bleomycin, phleomycin, chloramphenicol, Zeocin and mycophenolic acid. The selectable marker can also be a fluorescent protein selected from the group consisting of green fluorescent protein (GFP), enhanced GFP (eGFP), synthetic GFP, yellow fluorescent protein (YFP), enhanced YFP (eYFP), cyan fluorescent protein (CFP), mPlum, mCherry, tdTomato, mStrawberry, J-red, DsRed monomer, mOrange, mKO, mCitrine, Venus, YPet, Emerald6, CyPet, mCFPm, Cerulean and T-Sapphire.
[0872] In certain embodiments, the exogenous nucleotide sequence comprises a first RRS, a second RRS, and a third RRS, and at least one selectable marker located between the first RRS and the third RRS.
[0873] Exogenous nucleotide sequences are not derived from specific cells, but can be introduced into the cell by a DNA delivery method (such as, by a transfection method, an electroporation method or a transformation method). In certain embodiments, mammalian cells suitable for TI include at least one exogenous nucleotide sequence integrated into one or more integration sites in the mammalian cell genome. In certain embodiments, the exogenous nucleotide sequence is integrated into one or more integration sites in the specific locus of the mammalian cell genome.
[0874] In certain embodiments, the exogenous nucleotide sequence of integration comprises one or more recombination recognition sequences (RRS), wherein the RRS can be recognized by a recombinase. In certain embodiments, the exogenous nucleotide sequence of integration comprises at least two RRS. In certain embodiments, the exogenous nucleotide sequence of integration comprises three RRS, wherein the third RRS is located between the first RRS and the second RRS. In certain embodiments, the first RRS is identical to the second RRS, and the third RRS is different from the first RRS or the second RRS. In certain preferred embodiments, all three RRS are different. In certain embodiments, the RRS is independently selected from the group consisting of the following items: LoxP sequence, LoxP L3 sequence, LoxP 2L sequence, LoxFas sequence, Lox511 sequence, Lox2272 sequence, Lox2372 sequence, Lox5171 sequence, Loxm2 sequence, Lox71 sequence, Lox66 sequence, FRT sequence, Bxb1 attP sequence, Bxb1 attB sequence, φC31 attP sequence and φC31 attB sequence.
[0875] In certain embodiments, the exogenous nucleotide sequence of integration comprises at least one selective marker. In certain embodiments, the exogenous nucleotide sequence of integration comprises the first RRS, the second RRS and the third RRS, and at least one selective marker. In certain embodiments, the selective marker is located between the first RRS and the second RRS. In certain embodiments, two RRSs are flanked by at least one selective marker, that is, the first RRS is located at the 5' (upstream) of the selective marker and the second RRS is located at the 3' (downstream) of the selective marker. In certain embodiments, the first RRS is adjacent to the 5' end of the selective marker, and the second RRS is adjacent to the 3' end of the selective marker.
[0876] In certain embodiments, the selective marker is located between the first RRS and the second RRS, and the two flanking RRS are different. In certain preferred embodiments, the first flanking RRS is a LoxP L3 sequence, and the second flanking RRS is a LoxP 2L sequence. In certain embodiments, the LoxP L3 sequence is located at the 5' of the selective marker, and the LoxP 2L sequence is located at the 3' of the selective marker. In certain embodiments, the first flanking RRS is a wild-type FRT sequence, and the second flanking RRS is a mutant FRT sequence. In certain embodiments, the first flanking RRS is a Bxb1 attP sequence, and the second flanking RRS is a Bxb1 attB sequence. In certain embodiments, the first flanking RRS is a φC31 attP sequence, and the second flanking RRS is a φC31 attB sequence. In certain embodiments, the two RRS are positioned in the same orientation. In certain embodiments, the two RRS are both in a forward orientation or a reverse orientation. In certain embodiments, the two RRS are positioned in opposite orientations.
[0877] In certain embodiments, the integrated exogenous nucleotide sequence comprises a first selectable marker and a second selectable marker flanking two RRS, wherein the first selectable marker is different from the second selectable marker. In certain embodiments, the two selectable markers are independently selected from the group consisting of: glutamine synthetase selectable marker, thymidine kinase selectable marker, HYG selectable marker and puromycin resistance selectable marker. In certain embodiments, the integrated exogenous nucleotide sequence comprises a thymidine kinase selectable marker and a HYG selectable marker. In certain embodiments, the first selectable marker is selected from the group consisting of aminoglycoside phosphotransferase (APH) (e.g., hygromycin phosphotransferase (HYG), neomycin and G418 APH), dihydrofolate reductase (DHFR), thymidine kinase (TK), glutamine synthetase (GS), asparagine synthetase, tryptophan synthetase (indole), histidinol dehydrogenase (histidinol D), and genes encoding resistance to puromycin, blasticidin, bleomycin, phleomycin, chloramphenicol, Zeocin and mycophenolic acid, and the second selectable marker is selected from the group consisting of GFP, eGFP, synthetic GFP, YFP, eYFP, CFP, mPlum, mCherry, tdTomato, mStrawberry, J-red, DsRed monomer, mOrange, mKO, mCitrine, Venus, YPet, Emerald, CyPet, mCFPm, Cerulean and T-Sapphire fluorescent protein. In certain embodiments, the first selectable marker is a glutamine synthetase selectable marker and the second selectable marker is a GFP fluorescent protein. In certain embodiments, the two RRSs flanking the two selectable markers are different.
[0878] In certain embodiments, the selective marker is operably linked to a promoter sequence. In certain embodiments, the selective marker is operably linked to an SV40 promoter. In certain embodiments, the selective marker is operably linked to a human cytomegalovirus (CMV) promoter.
[0879] In certain embodiments, the exogenous nucleotide sequence of integration comprises three RRS. In certain embodiments, the 3rd RRS is located between the first RRS and the second RRS. In certain embodiments, the first RRS is identical to the second RRS, and the 3rd RRS is different from the first RRS or the second RRS. In certain preferred embodiments, all three RRS are different.
[0880] II.d Exemplary vectors suitable for practicing the present invention
[0881] In addition to the "single-vector RMCE" outlined above, a novel "dual-vector RMCE" can be performed to simultaneously target the integration of two nucleic acids.
[0882] In the method according to the present invention using the vector combination according to the present invention, a "dual vector RMCE" strategy is adopted. For example, but not by way of limitation, the integrated exogenous nucleotide sequence may comprise three RRSs, such as the following arrangement: wherein the third RRS ("RRS3") is present between the first RRS ("RRS1") and the second RRS ("RRS2"), and the first vector comprises two RRSs that match the first RRS and the third RRS on the integrated exogenous nucleotide sequence, and the second vector comprises two RRSs that match the third RRS and the second RRS on the integrated exogenous nucleotide sequence. An example of a dual vector RMCE strategy is Figure 1 Such a two-vector RMCE strategy allows the introduction of multiple SOIs by incorporating an appropriate number of SOIs in the corresponding sequence between each pair of RRSs, thereby obtaining an expression cassette organization according to the invention after TI in the genome of a mammalian cell suitable for TI.
[0883] The dual-plasmid RMCE strategy involves using three RRS sites to perform two independent RMCEs simultaneously ( Figure 1 ). Therefore, the landing site in mammalian cells suitable for TI using the dual-plasmid RMCE strategy includes a third RRS site (RRS3) that has no cross-activity with the first RRS site (RRS1) or the second RRS site (RRS2). The two expression plasmids to be targeted require the same flanking RRS sites for effective targeting, one expression plasmid (front) is flanked by RRS1 and RRS3, and the other expression plasmid (back) is flanked by RRS3 and RRS2. Two selective markers are also required in this dual-plasmid RMCE. A selective marker expression cassette is divided into two parts. The front plasmid will contain a promoter, followed by a start codon and an RRS3 sequence. The back plasmid will have an RRS3 sequence fused to the N-terminus of the selective marker coding region minus the start codon (ATG). It may be necessary to insert additional nucleotides between the RRS3 site and the selective marker sequence to ensure that the fusion protein undergoes in-frame translation (i.e., an operably linked). Only when both plasmids are correctly inserted will the complete expression cassette of the selective marker be assembled, and the cell will therefore be resistant to the corresponding selective agent. Figure 1 Schematic diagram showing the dual-plasmid RMCE strategy.
[0884] Both single-vector RMCE and dual-vector RMCE allow for the unidirectional integration of one or more donor DNA molecules into a predetermined site in the genome of a mammalian cell by precisely exchanging a DNA sequence present on the donor DNA with a DNA sequence in the genome of the mammalian cell where the integration site is located. These DNA sequences are characterized by two heterospecific RRSs flanked by: i) at least one selectable marker or, as in some dual-vector RMCEs, a "split selectable marker"; and / or ii) at least one exogenous SOI.
[0885] RMCE involves double recombination crossover events between two heterologous specific RRSs within the target genomic locus and donor DNA molecules, which are catalyzed by recombinases. RMCE is designed to introduce copies of DNA sequences from the combined front vector and back vector into a predetermined locus of the mammalian cell genome. Unlike recombination involving only one crossover event, RMCE can be implemented so that the prokaryotic vector sequence is not introduced into the genome of the mammalian cell, thereby reducing and / or preventing unnecessary triggering of host immune or defense mechanisms. The RMCE process can be repeated with multiple DNA sequences.
[0886] In certain embodiments, targeted integration is achieved by two RMCEs, wherein two different DNA sequences are integrated into predetermined sites of the genome of a mammalian cell suitable for TI, wherein each DNA sequence comprises at least one expression cassette encoding a portion of a heteromultimeric polypeptide and / or at least one selectable marker or portion thereof flanked by two heterospecific RRSs. In certain embodiments, targeted integration is achieved by multiple RMCEs, wherein DNA sequences from multiple vectors are all integrated into predetermined sites of the genome of a mammalian cell suitable for TI, wherein each DNA sequence comprises at least one expression cassette encoding a portion of a heteromultimeric polypeptide and / or at least one selectable marker or portion thereof flanked by two heterospecific RRSs. In certain embodiments, the selectable marker may be partially encoded on a first vector and partially encoded on a second vector, such that the selectable marker can only be expressed by correctly integrating both through double RMCE. An example of such a system is presented in Figure 1 middle.
[0887] In certain embodiments, targeted integration via recombinase-mediated recombination results in integration of the selectable marker and / or the different expression cassettes of the multimeric polypeptide into one or more predetermined integration sites of the host cell genome that are free of sequences from the prokaryotic vector.
[0888] In addition to the various embodiments depicted and claimed, the disclosed subject matter also relates to other embodiments having other combinations of features disclosed and claimed herein. Thus, the specific features presented herein may be combined with each other in other ways within the scope of the disclosed subject matter, such that the disclosed subject matter includes any suitable combination of features disclosed herein. For purposes of illustration and description, the foregoing description of specific embodiments of the disclosed subject matter has been presented. It is not intended to be exhaustive or to limit the disclosed subject matter to those embodiments disclosed.
[0889] It is obvious to those skilled in the art that various modifications and changes can be made to the composition and method of the disclosed subject matter without departing from the spirit or scope of the disclosed subject matter. Therefore, it is intended that the disclosed subject matter includes modifications and changes within the scope of the attached claims and their equivalents.
[0890] Various publications, patents, and patent applications are cited herein, the contents of which are incorporated by reference in their entirety.
[0891] The following examples and drawings are provided to aid the understanding of the present invention, the true scope of the invention being set forth in the appended claims.
[0892] Sequence Description
[0893] SEQ ID NO:01: Exemplary sequence of L3 recombinase recognition sequence
[0894] SEQ ID NO:02:2L Exemplary sequence of recombinase recognition sequence
[0895] SEQ ID NO:03: Exemplary sequence of LoxFas recombinase recognition sequence
[0896] SEQ ID NO: 04-06: Exemplary variants of the human CMV promoter
[0897] SEQ ID NO:07: Exemplary SV40 polyadenylation signal sequence
[0898] SEQ ID NO:08: Exemplary bGH polyadenylation signal sequence
[0899] SEQ ID NO:09: Exemplary hGT terminator sequence
[0900] SEQ ID NO: 10: Exemplary SV40 promoter sequence
[0901] SEQ ID NO: 11: Exemplary GFP nucleic acid sequence
[0902] Examples
[0903] Example 1
[0904] General techniques
[0905] 1) Recombinant DNA technology
[0906] Standard methods were used to manipulate DNA, such as described in Sambrook et al., Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, (1989). Molecular biology reagents were used according to the manufacturer's instructions.
[0907] 2) DNA sequence determination
[0908] DNA sequencing was performed at SequiServe GmbH (Vaterstetten, Germany).
[0909] 3) DNA and protein sequence analysis and sequence data management
[0910] The EMBOSS (European Molecular Biology Open Software Suite) software package and Invitrogen's Vector NTI version 11.5 or Geneious Prime were used for sequence creation, mapping, analysis, annotation, and illustration.
[0911] 4) Gene and oligonucleotide synthesis
[0912] The desired gene fragments were prepared by chemical synthesis at Geneart GmbH (Regensburg, Germany). The synthesized gene fragments were cloned into E. coli plasmids for propagation / amplification. The DNA sequence of the subcloned gene fragments was verified by DNA sequencing. Alternatively, short synthetic DNA fragments were assembled by annealing chemically synthesized oligonucleotides or by PCR. Individual oligonucleotides were prepared by metabion GmbH (Planegg-Martinsried, Germany).
[0913] 5) Reagents
[0914] All commercial chemicals, antibodies, and kits were used according to the manufacturers’ protocols if not stated otherwise.
[0915] 6) Cultivation of TI host cell lines
[0916] TI CHO host cells were cultured at 37°C in a humidified incubator with 85% humidity and 5% CO2. They were cultured in a proprietary DMEM / F12 base medium containing 300 μg / ml hygromycin B and 4 μg / ml of a second selection marker. The cells were passaged every 3 or 4 days at a concentration of 0.3x10E6 cells / ml in a total volume of 30 ml. For the culture, 125 ml unbaffled conical shake flasks were used. The cells were shaken at a speed of 150 rpm with an amplitude of 5 cm. The cell count was determined using a Cedex HiRes Cell Counter (Roche). The cells were kept in culture until they reached 60 days of age.
[0917] 7) Cloning
[0918] conventional
[0919] Cloning using the R site depends on the DNA sequence next to the target gene (SOI), which is equal to the sequence located in the following fragment. Similarly, the assembly of fragments is possible by overlapping the same sequence and then sealing the nicks in the assembled DNA by DNA ligase. Therefore, it is necessary to clone individual genes, especially preliminary vectors containing the correct R site. After the successful cloning of these preliminary vectors, the target gene flanking the R site is cut off by restriction digestion by an enzyme that cuts directly next to the R site. The last step is to assemble all DNA fragments in one step. In more detail, 5'-nuclease removes the 5'-end of the overlapping region (R-site). After that, annealing of the R site can be performed, and DNA polymerase extends the 3' end to fill the gap in the sequence. Finally, DNA ligase seals the gap between nucleotides. Add an assembly premix containing different enzymes (such as exonucleases, DNA polymerases and ligases), and then incubate the reaction mixture at 50°C to assemble these individual fragments into a plasmid. After that, the competent E. coli cells are transformed with the plasmid.
[0920] For some vectors, a cloning strategy by restriction enzymes is used. By selecting the appropriate restriction endonuclease, the target gene can be cut and then inserted into different vectors by connection. Therefore, it is preferred to use an enzyme that cuts at the multiple cloning site (MCS) and select it in a clever way so that the connection of the fragments can be carried out in the correct array. If the vector and the fragment are cut with the same restriction enzyme before, the sticky ends of the fragment and the vector will fit together perfectly and can be connected by DNA ligase subsequently. After connection, the competent E. coli cells are transformed with the newly generated plasmid.
[0921] Cloning by restriction digestion
[0922] To digest the plasmid with restriction enzymes, pipette the following components together on ice:
[0923] Table: Restriction digestion reaction mixture
[0924]
[0925] If more enzymes were used in one digestion, 1 μl of each enzyme was used and the volume was adjusted by adding more or less PCR grade water. All enzymes were chosen on the basis that they were qualified for use with CutSmart buffer from New England Biolabs (100% active) and had the same incubation temperature (all 37°C).
[0926] The incubation was performed using a thermomixer or thermocycler, allowing the samples to incubate at a constant temperature (37°C). During the incubation, the samples were not agitated. The incubation time was set to 60 minutes. The samples were then mixed directly with the loading dye and loaded onto an agarose electrophoresis gel or stored at 4°C / ice for further use.
[0927] A 1% agarose gel was prepared for gel electrophoresis. Therefore, 1.5 g of multipurpose agarose was weighed into a 125 conical shake flask and filled with 150 ml of TAE buffer. The mixture was heated in a microwave oven until the agarose was completely dissolved. 0.5 μg / ml ethidium bromide was added to the agarose solution. Thereafter the gel was cast in a mold. After the agarose solidified, the mold was placed in the electrophoresis chamber and the electrophoresis chamber was filled with TAE buffer. The sample was then loaded. In the first pocket (starting from the left), the appropriate DNA molecular weight marker was loaded, followed by the sample. The gel was run at <130 V for approximately 60 minutes. After electrophoresis, the gel was removed from the chamber and analyzed in a UV imager.
[0928] The target band was excised and transferred to a 1.5 ml Eppendorf tube. For gel purification, the QIAquick Gel Extraction Kit from Qiagen was used according to the manufacturer's instructions. The DNA fragments were stored at -20 °C for further use.
[0929] The fragments for ligation are pipetted together in a vector-insert molar ratio of 1:2, 1:3 or 1:5, depending on the length of the insert and vector fragments and their relationship to each other. If the fragment that should be inserted into the vector is short, a ratio of 1:5 is used. If the insert is long, a smaller amount of insert is used in relation to the vector. An amount of 50 ng of vector is used per ligation, and the specific amount of insert is calculated using the NEBioCalculator. For ligation, the T4 DNA Ligation Kit from NEB is used. The following table describes an example of a ligation mix:
[0930] Table: Ligation Reaction Mixture
[0931]
[0932] Start by mixing the DNA and water, add the buffer, and finally the enzyme, pipetting all components together on ice. Gently mix the reaction by pipetting up and down, briefly microcentrifuge, and then incubate at room temperature for 10 minutes. After incubation, heat inactivate the T4 ligase at 65°C for 10 minutes. Cool the sample on ice. In the last step, 10-beta competent E. coli cells are transformed with 2 μl of the ligated plasmid (see below).
[0933] Cloning by R site assembly
[0934] For assembly, all DNA fragments with R sites at the ends were pipetted together on ice. When assembling more than 4 fragments, all fragments were used in an equimolar ratio (0.05 ng) as recommended by the manufacturer. Half of the reaction mixture was prepared by NEBuilder HiFi DNA Assembly Master Mix. The total reaction volume was 40 μl and was reached by filling with PCR clean water. An exemplary pipetting scheme is described in the table below.
[0935] Table: Assembly reaction mixture
[0936]
[0937] After the reaction mixture was set up, the tubes were incubated in a thermocycler at a constant 50° C. for 60 minutes. After successful assembly, 2 μl of assembled plasmid DNA was used to transform 10-β competent E. coli (see below).
[0938] Transformation of 10-β competent E. coli cells
[0939] For transformation, 10-β competent E. coli cells were thawed on ice. Afterwards, 2 μl of plasmid DNA was directly transferred into the cell suspension. The tube was flicked and placed on ice for 30 minutes. Thereafter, the cells were placed in a 42°C warm heat block and heat shocked for exactly 30 seconds. Next, the cells were cooled on ice for 2 minutes. 950 μl of NEB 10-β growth medium was added to the cell suspension. The cells were incubated at 37°C with shaking for one hour. Then, 50-100 μl was pipetted onto a preheated (37°C) LB-Amp agar plate and smeared with a disposable spatula. The plate was incubated at 37°C overnight. Only bacteria that successfully incorporated a plasmid carrying the ampicillin resistance gene could grow on this plate. A single colony was picked the next day and cultured in LB-Amp medium for subsequent plasmid preparation.
[0940] Bacterial culture
[0941] The cultivation of E. coli was carried out in LB medium (short for Luria Bertani) to which 1 ml / L of 100 mg / ml ampicillin was added, resulting in an ampicillin concentration of 0.1 mg / ml. For different amounts of plasmid preparation, the following amounts were inoculated with a single bacterial colony.
[0942] Table: E. coli culture volume
[0943] Quantitative plasmid preparation Volume LB-Amp medium [ml] Incubation time [h] Mini-Prep 96-well (EpMotion) 1,5 23 Mini-Prep 15ml-Tube 3,6 23 Maxi-Prep 200 16
[0944] For Mini-Prep, 96-well 2 ml deep well plates were filled with 1.5 ml LB-Amp medium per well. Colonies were picked and toothpicks were inserted into the medium. After all colonies were picked, the plate was sealed with a sticky air porous membrane. The cells were incubated in an incubator at 37°C with shaking speed of 200 rpm for 23 hours.
[0945] For Mini-Prep, 3.6 ml of LB-Amp medium was placed in a 15 ml tube (with vented cap) and inoculated with the same bacterial colony. The toothpick was not removed during the incubation but remained in the tube. As with the 96-well plate, the tube was incubated at 37°C, 200 rpm for 23 hours.
[0946] For Maxi-Prep, 200 ml of LB-Amp medium was filled into an autoclaved 1 L Erlenmeyer glass flask and inoculated with 1 ml of an approximately 5 hour old bacterial day culture. The flask was closed with a paper stopper and incubated at 37°C, 200 rpm for 16 hours.
[0947] Plasmid preparation
[0948] For Mini-Prep, 50 μl of bacterial suspension was transferred to a 1 ml deep well plate. Afterwards, the bacterial cells were centrifuged in the plate at 3000 rpm, 4°C for 5 minutes. The supernatant was removed and the plate with the bacterial pellet was placed in the EpMotion. After approximately 90 minutes the run was complete and the eluted plasmid DNA could be removed from the EpMotion for further use.
[0949] For Mini-Prep, remove the 15 ml tube from the incubator and divide 3.6 ml of the bacterial culture into two 2 ml Eppendorf tubes. Centrifuge the tubes at 6,800 x g for 3 minutes at room temperature in a benchtop microcentrifuge. Afterwards, perform Mini-Prep using the Qiagen QIAprep Spin Miniprep kit according to the manufacturer's instructions. Measure the plasmid DNA concentration with a Nanodrop.
[0950] Maxi-Prep was prepared according to the manufacturer's instructions using Macherey-Nagel Xtra MaxiEF kit was used. DNA concentration was measured with Nanodrop.
[0951] Ethanol precipitation
[0952] Mix a certain volume of DNA solution with 2.5 times the volume of 100% ethanol. Incubate the mixture at -20°C for 10 minutes. Then centrifuge the DNA at 14,000rpm, 4°C for 30 minutes. Carefully remove the supernatant and wash the pellet with 70% ethanol. Centrifuge the tube again at 14,000rpm, 4°C for 5 minutes. Carefully remove the supernatant by pipetting and dry the pellet. After the ethanol evaporates, add an appropriate amount of endotoxin-free water. Give the DNA time to redissolve in water at 4°C overnight. Take a small portion and measure the DNA concentration with a Nanodrop device.
[0953] Example 2
[0954] Plasmid generation
[0955] Expression cassette composition
[0956] For the expression of antibody chains, a transcription unit containing the following functional elements was used:
[0957] - The immediate early enhancer and promoter from human cytomegalovirus, including intron A,
[0958] - human heavy chain immunoglobulin 5'-untranslated region (5'UTR),
[0959] - mouse immunoglobulin heavy chain signal sequence,
[0960] - a nucleic acid encoding the corresponding antibody chain,
[0961] - bovine growth hormone polyadenylation sequence (BGH pA), and
[0962] - Optionally, human gastrin terminator (hGT).
[0963] In addition to the expression unit / cassette containing the desired gene to be expressed, the basic / standard mammalian expression plasmid also contains
[0964] - an origin of replication from the vector pUC18, which allows replication of this plasmid in E. coli, and
[0965] -β-lactamase gene, which confers ampicillin resistance in Escherichia coli.
[0966] Front and back vector cloning
[0967] To construct the double plasmid antibody construct, the antibody HC and LC fragments were cloned into the front vector backbone containing L3 and LoxFAS sequences and the back vector containing LoxFAS and 2L sequences and the pac selection marker. The Cre recombinase plasmid pOG231 (Wong, ET, et al., Nucleic Acids Res 2005, 33, (17), e147; O'Gorman S et al., Proc. Natl. Acad. Sci. USA 1997, 94, (26), 14602-7) was used for all RMCE processes.
[0968] cDNA encoding each antibody chain is produced by gene synthesis (Geneart, Life Technologies Inc.).Gene synthesis vector and backbone vector were digested with HindIII-HF and EcoRI-HF (NEB) at 37°C for 1 hour, and separated by agarose gel electrophoresis.Insert and backbone DNA fragments were cut from agarose gel, and extracted by QIAquick gel extraction kit (Qiagen).Purified insert fragments and backbone fragments were connected with an insert / backbone ratio of 3:1 via a quick ligation kit (Roche) according to the manufacturer's scheme.Then the ligation method was transformed into competent Escherichia coli DH5α via heat shock at 42°C for 30 seconds, and incubated at 37°C for 1 hour, and then plated on agar plates containing ampicillin for selection.The plates were incubated overnight at 37°C.
[0969] The next day, colonies were picked and incubated overnight at 37°C with shaking to prepare either a minimal or maximal preparation, which was performed using 5075 (Eppendorf) or QIAprep Spin Mini-Prep Kit (Qiagen) / NucleoBond Xtra Maxi EF Kit (Macherey & Nagel). All constructs were sequenced to ensure the absence of any unwanted mutations (SequiServe GmbH).
[0970] In the second cloning step, the previously cloned vector was digested with KpnI-HF / SalI-HF and SalI-HF / MfeI-HF, the same conditions as the first cloning. The TI backbone vector was digested with KpnI-HF and MfeI–HF. Isolation and extraction were performed as described above. The purified insert and backbone were ligated using T4 DNA ligase (NEB) at a ratio of 1:1:1 insert / insert / backbone at 4°C overnight and inactivated at 65°C for 10 min according to the manufacturer's protocol. The following cloning steps were performed as described above.
[0971] The cloned plasmids were used for TI transfection and pool generation.
[0972] Example 3
[0973] Culture, transfection, selection and single cell cloning
[0974] TI host cells were propagated in a DMEM / F12-based proprietary culture medium in a disposable 125 ml ventilated shake flask at a constant stirring rate of 150 rpm under standard humidified conditions (95% rH, 37°C and 5% CO2). Cells were inoculated in a chemically defined medium containing effective concentrations of selection marker 1 and selection marker 2 at a concentration of 3x10E5 cells / ml every 3-4 days. The density and viability of the culture were measured using a Cedex HiRes cell counter (F. Hoffmann-La Roche Ltd, Basel, Switzerland).
[0975] For stable transfection, equimolar amounts of the front and back vectors were mixed. 1 μg of Cre expression plasmid was added to 5 μg of the mixture.
[0976] Two days before transfection, TI host cells were seeded in fresh culture medium at a density of 4x10E5 cells / ml. Transfection was performed by Nucleofector device using Nucleofector Kit V (Lonza, Switzerland) according to the manufacturer's protocol. 3x10E7 cells were transfected with 30 μg of plasmid. After transfection, cells were seeded in 30 ml culture medium without selection agent.
[0977] On the 5th day after inoculation, the cells were centrifuged and transferred to 80 mL of chemically defined medium containing puromycin (selection agent 1) and 1-(2'-deoxy-2'-fluoro-1-β-D-arabinofuranosyl-5-iodo) uracil (FIAU; selection agent 2) at an effective concentration of 6x10E5 cells / ml for selection of recombinant cells. From this day on, the cells were incubated at 37°C, 150rpm, 5% CO2 and 85% humidity without passage. The cell density and viability of the culture were monitored regularly. When the viability of the culture began to increase again, the concentrations of selection agents 1 and 2 were reduced to approximately half of the amount previously used. More specifically, to facilitate the recovery of cells, the selection pressure was reduced if the viability was >40% and the viable cell density (VCD) was >0.5x10E6 cells / mL. Therefore, 4x10E5 cells / ml were centrifuged and resuspended in 40 ml of selective medium II (chemically defined medium, 1 / 2 selective markers 1 and 2). The cells were incubated under the same conditions as before and also without splitting.
[0978] Ten days after the start of selection, the expression of intracellular GFP and the binding of extracellular trivalent antibodies (TCB) to the cell surface were measured by flow cytometry to check whether the Cre-mediated box exchange was successful. APC antibodies (F(ab')2 fragment goat anti-human IgG labeled with allophycocyanin) for human antibody light and heavy chains were used for FACS staining. Flow cytometry was performed using a BD FACS Canto II flow cytometer (BD, Heidelberg, Germany). Ten thousand events for each sample were measured. Live cells were gated in the forward scatter (FSC) to side scatter (SSC) graph. The live cell gate was defined by untransfected TI host cells and applied to all samples using FlowJo 7.6.5EN software (TreeStar, Olten, Switzerland). The fluorescence of GFP was quantified in the FITC channel (excitation at 488nm and detection at 530nm). Trivalent antibodies (TCB) were measured in the APC channel (excitation at 645nm and detection at 660nm). Parental CHO cells, those used to generate TI host cells, served as negative controls for GFP and trivalent antibody (TCB) expression.Fourteen days after the start of selection, the viability exceeded 90% and the selection was considered complete.
[0979] Example 4
[0980] FACS screening
[0981] FACS analysis was performed to check transfection efficiency and RMCE efficiency of transfection. 4×10E5 cells of the transfected method were centrifuged (1200 rpm, 4 min) and washed twice with 1 mL PBS. After the washing step with PBS, the pellet was resuspended in 400 μL PBS and transferred to a FACS tube (with a cell strainer cap). The FACS Canto II was used for measurement, and the data were analyzed by FlowJo software.
[0982] Example 5
[0983] Fed-batch culture
[0984] In shake flasks or Ambr15 containers (Sartorius Stedim), batch feed production culture is carried out using a proprietary chemical composition-defined culture medium. Day 0, cells are inoculated at a density of 1x10E6 cells / mL; Temperature is changed on the 3rd day. On the 3rd, 7th and 10th days, a proprietary feed matrix is added to the culture. On the 0th, 3rd, 7th, 10th and 14th days, a Vi-CellTMXR instrument (Beckman Coulter) is used to measure the viable cell count (VCC) and cell viability percentage in the culture. On the 7th, 10th and 14th days, a Bioprofile 400 analyzer (Nova Biomedical) is used to measure glucose and lactate concentrations. 14 days after the start of batch feeding, supernatants are harvested by centrifugation (10min, 1000rpm, and 10min, 4000rpm), and clarified by filtration (0.22 μm). The titer on the 14th day is determined using protein A affinity chromatography with UV detection.
[0985] Product quality was confirmed by Caliper's LabChip (Caliper Life Sciences).
[0986] Example 6
[0987] Effect of vector design
[0988] To examine the effect of expression cassette organization on TI host productivity, RMCE libraries were generated by transfecting two plasmids (front vector and back vector) including different numbers and organizations of individual chains of trivalent antibodies in TCB format. After selection, recovery and verification of RMCE by flow cytometry, the productivity of the library was evaluated in a 14-day batch feed production trial. For specific vector organization, an increase in titer was observed compared to the reference library.
[0989] The effect of antibody chain expression cassette organization on the expression of five different TCBs was evaluated. TCBs 1 to 5 all have different targeting specificities. TCB 3 was tested with 4 different anti-CD3 binding sites.
[0990] For TCB-1, the following results have been obtained; the reference tissue is shaded grey:
[0991]
[0992]
[0993] For TCB-3, the following results have been obtained:
[0994]
[0995] For TCB-2, -4 and -5, the following results have been obtained:
[0996]
[0997]
[0998] MP = main product, eff.Titer = effective titer = titer times % main product
Claims
1. A deoxyribonucleic acid encoding a trivalent antibody, which comprises only the following expression cassette in the 5' to 3' direction (1) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second heavy chain, and - a fifth expression cassette encoding the second light chain, or (2) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding the second heavy chain, - a fifth expression cassette encoding the second light chain, - a sixth expression cassette encoding the second light chain, or (3) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding the second light chain, - a fifth expression cassette encoding the second light chain, or (4) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding the second light chain, - a fifth expression cassette encoding the first heavy chain, - a sixth expression cassette encoding the second light chain, or (5) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding the second light chain, - a fifth expression cassette encoding the second heavy chain, - a sixth expression cassette encoding the second light chain, - a seventh expression cassette encoding the second light chain, or (6) - a first expression cassette encoding a first light chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first heavy chain, - a fourth expression cassette encoding the second heavy chain, - a fifth expression cassette encoding the second light chain, - a sixth expression cassette encoding the second light chain, wherein the first heavy chain comprises in the CH3 domain the mutation T366W according to Kabat numbering and the second heavy chain comprises in the CH3 domain the mutations T366S, L368A and Y407V according to Kabat numbering, or vice versa; in - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain, wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; in, Each of the expression cassettes comprises, in the 5' to 3' direction, the same promoter, coding sequence and the same polyadenylation signal sequence.
2. The deoxyribonucleic acid encoding a trivalent antibody according to claim 1, wherein Each of the expression cassettes comprises, in the 5' to 3' direction, the same promoter, the coding sequence and the same polyadenylation signal sequence followed by a terminator sequence.
3. Deoxyribonucleic acid according to claim 2, wherein one of the heavy chains further comprises the mutation S354C and the corresponding other heavy chain comprises the mutation Y349C according to Kabat numbering.
4. The deoxyribonucleic acid according to claim 2, wherein the first heavy chain is an extended heavy chain comprising an additional domain-exchanged Fab fragment.
5. The deoxyribonucleic acid according to claim 3, wherein the first heavy chain is an extended heavy chain comprising an additional domain-exchanged Fab fragment.
6. The deoxyribonucleic acid of claim 2, wherein the deoxyribonucleic acid is stably integrated into the genome of a mammalian cell at a single site or locus.
7. The deoxyribonucleic acid of claim 3, wherein the deoxyribonucleic acid is stably integrated into the genome of a mammalian cell at a single site or locus.
8. The deoxyribonucleic acid of claim 4, wherein the deoxyribonucleic acid is stably integrated into the genome of a mammalian cell at a single site or locus.
9. The deoxyribonucleic acid of claim 5, wherein the deoxyribonucleic acid is stably integrated into the genome of a mammalian cell at a single site or locus.
10. The deoxyribonucleic acid according to claim 2, comprising an additional expression cassette encoding a selectable marker.
11. The deoxyribonucleic acid according to claim 3, comprising an additional expression cassette encoding a selectable marker.
12. The deoxyribonucleic acid according to claim 4, comprising an additional expression cassette encoding a selectable marker.
13. The deoxyribonucleic acid according to claim 5, comprising an additional expression cassette encoding a selectable marker.
14. The deoxyribonucleic acid according to claim 6, comprising an additional expression cassette encoding a selectable marker.
15. The deoxyribonucleic acid according to claim 7, comprising an additional expression cassette encoding a selectable marker.
16. The deoxyribonucleic acid according to claim 8, comprising an additional expression cassette encoding a selectable marker.
17. The deoxyribonucleic acid according to claim 9, comprising an additional expression cassette encoding a selectable marker.
18. The deoxyribonucleic acid of claim 10, wherein for the expression cassette encoding the selection marker in addition, the promoter is the human CMV promoter with intron A, the polyadenylation signal sequence is the bGH polyadenylation signal sequence, and the terminator is the hGT terminator, wherein for the expression cassette encoding the selection marker, the promoter is the SV40 promoter, the polyadenylation signal sequence is the SV40 polyadenylation signal sequence, and the terminator is absent.
19. The deoxyribonucleic acid of claim 11, wherein for all but the expression cassette encoding the selection marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selection marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
20. The deoxyribonucleic acid of claim 12, wherein for all but the expression cassette encoding the selection marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selection marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
21. The deoxyribonucleic acid of claim 13, wherein for all but the expression cassette encoding the selection marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selection marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
22. The deoxyribonucleic acid of claim 14, wherein for all but the expression cassette encoding the selection marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selection marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
23. The deoxyribonucleic acid of claim 15, wherein for all but the expression cassette encoding the selection marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selection marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
24. The deoxyribonucleic acid of claim 16, wherein for all but the expression cassette encoding the selection marker, the promoter is the human CMV promoter with intron A, the polyadenylation signal sequence is the bGH polyadenylation signal sequence, and the terminator is the hGT terminator, wherein for the expression cassette encoding the selection marker, the promoter is the SV40 promoter, the polyadenylation signal sequence is the SV40 polyadenylation signal sequence, and the terminator is absent.
25. The deoxyribonucleic acid of claim 17, wherein for all but the expression cassette encoding the selection marker, the promoter is the human CMV promoter with intron A, the polyadenylation signal sequence is the bGH polyadenylation signal sequence, and the terminator is the hGT terminator, wherein for the expression cassette encoding the selection marker, the promoter is the SV40 promoter, the polyadenylation signal sequence is the SV40 polyadenylation signal sequence, and the terminator is absent.
26. The deoxyribonucleic acid of claim 6, wherein the mammalian cell is a CHO cell.
27. The deoxyribonucleic acid of claim 7, wherein the mammalian cell is a CHO cell.
28. The deoxyribonucleic acid of claim 8, wherein the mammalian cell is a CHO cell.
29. The deoxyribonucleic acid of claim 9, wherein the mammalian cell is a CHO cell.
30. The deoxyribonucleic acid according to claim 1 or 2, wherein the organization in the 5' to 3' direction has as the first expression cassette an expression cassette encoding the first heavy chain, all cassettes being arranged unidirectionally.
31. The deoxyribonucleic acid according to claim 1 or 2, wherein the organization in the 5' to 3' direction is a first expression cassette encoding a first light chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, and a sixth expression cassette encoding a second light chain, wherein the first expression cassette to the third expression cassette are arranged unidirectionally and the fourth expression cassette to the sixth expression cassette are arranged unidirectionally, whereby the first expression cassette to the third expression cassette are arranged in the opposite direction of the fourth expression cassette to the sixth expression cassette.
32. A method for producing a trivalent antibody comprising the following steps: a) culturing a mammalian cell comprising a deoxyribonucleic acid encoding a trivalent antibody according to any one of claims 1 to 31, and b) recovering the trivalent antibody from the cells or culture medium, wherein the deoxyribonucleic acid encoding the trivalent antibody is stably integrated into the genome of the mammalian cell and comprises only the following expression cassette in the 5' to 3' direction (1) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second heavy chain, and - a fifth expression cassette encoding the second light chain, or (2) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding the second heavy chain, - a fifth expression cassette encoding the second light chain, - a sixth expression cassette encoding the second light chain, or (3) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding the second light chain, - a fifth expression cassette encoding the second light chain, or (4) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding the second light chain, - a fifth expression cassette encoding the first heavy chain, - a sixth expression cassette encoding the second light chain, or (5) - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding the second light chain, - a fifth expression cassette encoding the second heavy chain, - a sixth expression cassette encoding the second light chain, - a seventh expression cassette encoding the second light chain, or (6) - a first expression cassette encoding a first light chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first heavy chain, - a fourth expression cassette encoding the second heavy chain, - a fifth expression cassette encoding the second light chain, - a sixth expression cassette encoding the second light chain, wherein the first heavy chain comprises in the CH3 domain the mutation T366W according to Kabat numbering and the second heavy chain comprises in the CH3 domain the mutations T366S, L368A and Y407V according to Kabat numbering, or vice versa; in - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain, wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; Therein, each of the expression cassettes comprises the same promoter, coding sequence and the same polyadenylation signal sequence in the 5' to 3' direction.
33. The method for producing a trivalent antibody according to claim 32, wherein: Each of the expression cassettes comprises, in the 5' to 3' direction, the same promoter, the coding sequence and the same polyadenylation signal sequence followed by a terminator sequence.
34. Use of the deoxyribonucleic acid according to any one of claims 1 to 31 for expressing a trivalent antibody in mammalian cells in vitro.
35. A recombinant mammalian cell comprising the deoxyribonucleic acid of any one of claims 1 to 31 encoding the trivalent antibody integrated into the genome of the cell.
36. A composition comprising two deoxyribonucleic acids, the two deoxyribonucleic acids further comprising three different recombination recognition sequences and five to seven expression cassettes, wherein - The first deoxyribonucleic acid contains only the following expression cassette in the 5' to 3' direction (1) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first light chain, and - a first copy of the third recombination recognition sequence, or (2) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first light chain, and - a first copy of the third recombination recognition sequence, or (3) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of the third recombination recognition sequence, or (4) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of the third recombination recognition sequence, or (5) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of the third recombination recognition sequence, or (6) - a first recombination recognition sequence, - a first expression cassette encoding a first light chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first heavy chain, and - a first copy of a third recombination recognition sequence, and - the second deoxyribonucleic acid comprises in the 5' to 3' direction (1) - a second copy of the third recombination recognition sequence, - a fourth expression cassette encoding the second heavy chain, - a fifth expression cassette encoding a second light chain, and - a second recombination recognition sequence, or (2) - a second copy of the third recombination recognition sequence, - a fourth expression cassette encoding the second heavy chain, - a fifth expression cassette encoding the second light chain, - a sixth expression cassette encoding the second light chain, and - a second recombination recognition sequence, or (3) - a second copy of the third recombination recognition sequence, - a fifth expression cassette encoding a second light chain, and - a second recombination recognition sequence, or (4) - a second copy of the third recombination recognition sequence, - a fifth expression cassette encoding the first heavy chain, - a sixth expression cassette encoding the second light chain, and - a second recombination recognition sequence, or (5) - a second copy of the third recombination recognition sequence, - a fifth expression cassette encoding the second heavy chain, - a sixth expression cassette encoding the second light chain, - a seventh expression cassette encoding the second light chain, and - a second recombination recognition sequence, or (6) - a second copy of the third recombination recognition sequence, - a fourth expression cassette encoding the second heavy chain, - a fifth expression cassette encoding the second light chain, - a sixth expression cassette encoding the second light chain, and - a second recombination recognition sequence, wherein the first heavy chain comprises in the CH3 domain the mutation T366W according to Kabat numbering and the second heavy chain comprises in the CH3 domain the mutations T366S, L368A and Y407V according to Kabat numbering, or vice versa; in - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain, wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; in, Each of the expression cassettes comprises, in the 5' to 3' direction, the same promoter, coding sequence and the same polyadenylation signal sequence.
37. The composition comprising two deoxyribonucleic acids according to claim 36, wherein: Each of the expression cassettes comprises, in the 5' to 3' direction, the same promoter, the coding sequence and the same polyadenylation signal sequence followed by a terminator sequence.
38. The composition of claim 37, wherein one of the heavy chains further comprises the mutation S354C and the corresponding other heavy chain comprises the mutation Y349C according to Kabat numbering.
39. The composition of claim 37, wherein the first heavy chain is an extended heavy chain comprising an additional domain-exchanged Fab fragment.
40. The composition of claim 38, wherein the first heavy chain is an extended heavy chain comprising an additional domain-swapped Fab fragment.
41. The composition of claim 37, wherein the deoxyribonucleic acid is stably integrated into the genome of a mammalian cell at a single site or locus.
42. The composition of claim 38, wherein the deoxyribonucleic acid is stably integrated into the genome of a mammalian cell at a single site or locus.
43. The composition of claim 39, wherein the deoxyribonucleic acid is stably integrated into the genome of a mammalian cell at a single site or locus.
44. The composition of claim 40, wherein the deoxyribonucleic acid is stably integrated into the genome of a mammalian cell at a single site or locus.
45. The composition of claim 37, comprising an additional expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is located partially 5' to a third recombination recognition sequence and partially 3' to the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal, wherein the start codon is operably linked to the coding sequence.
46. The composition of claim 38, comprising an additional expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is partially located 5' of a third recombination recognition sequence and partially located 3' of the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal, wherein the start codon is operably linked to the coding sequence.
47. The composition of claim 39, comprising an additional expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is partially located 5' of a third recombination recognition sequence and partially located 3' of the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal, wherein the start codon is operably linked to the coding sequence.
48. The composition of claim 40, comprising an additional expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is partially located 5' of a third recombination recognition sequence and partially located 3' of the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal, wherein the start codon is operably linked to the coding sequence.
49. The composition of claim 41, comprising an additional expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is partially located 5' of a third recombination recognition sequence and partially located 3' of the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal, wherein the start codon is operably linked to the coding sequence.
50. The composition of claim 42, comprising an additional expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is located partially 5' to a third recombination recognition sequence and partially 3' to the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal, wherein the start codon is operably linked to the coding sequence.
51. The composition of claim 43, comprising an additional expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is partially located 5' of a third recombination recognition sequence and partially located 3' of the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal, wherein the start codon is operably linked to the coding sequence.
52. The composition of claim 44, comprising an additional expression cassette encoding a selectable marker, wherein the expression cassette encoding the selectable marker is located partially 5' to a third recombination recognition sequence and partially 3' to the third recombination recognition sequence, wherein the 5' portion of the expression cassette comprises a promoter and a start codon, and the 3' portion of the expression cassette comprises a coding sequence without a start codon and a poly A signal, wherein the start codon is operably linked to the coding sequence.
53. The composition of claim 45, wherein for excluding the expression cassette encoding the selectable marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selectable marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
54. The composition of claim 46, wherein for excluding the expression cassette encoding the selectable marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selectable marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
55. The composition of claim 47, wherein for all but the expression cassette encoding the selectable marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selectable marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
56. The composition of claim 48, wherein for all but the expression cassette encoding the selectable marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selectable marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
57. The composition of claim 49, wherein for all but the expression cassette encoding the selectable marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selectable marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
58. The composition of claim 50, wherein for excluding the expression cassette encoding the selectable marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selectable marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
59. The composition of claim 51, wherein for all but the expression cassette encoding the selectable marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selectable marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
60. The composition of claim 52, wherein for all but the expression cassette encoding the selectable marker, the promoter is a human CMV promoter with intron A, the polyadenylation signal sequence is a bGH polyadenylation signal sequence, and the terminator is an hGT terminator, wherein for the expression cassette encoding the selectable marker, the promoter is an SV40 promoter, the polyadenylation signal sequence is an SV40 polyadenylation signal sequence, and the terminator is absent.
61. The composition of claim 41, wherein the mammalian cell is a CHO cell.
62. The composition of claim 42, wherein the mammalian cell is a CHO cell.
63. The composition of claim 43, wherein the mammalian cell is a CHO cell.
64. The composition of claim 44, wherein the mammalian cell is a CHO cell.
65. The composition of claim 36 or 37, wherein the organization in the 5' to 3' direction has as the first expression cassette the expression cassette encoding the first heavy chain, all cassettes being arranged unidirectionally.
66. The composition of claim 36 or 37, wherein the organization in the 5' to 3' direction is a first expression cassette encoding a first light chain, a second expression cassette encoding a first light chain, a third expression cassette encoding a first heavy chain, a fourth expression cassette encoding a second heavy chain, a fifth expression cassette encoding a second light chain, a sixth expression cassette encoding a second light chain, the first expression cassette to the third expression cassette being arranged unidirectionally and the fourth expression cassette to the sixth expression cassette being arranged unidirectionally, whereby the first expression cassette to the third expression cassette are arranged in the opposite direction of the fourth expression cassette to the sixth expression cassette.
67. A method for producing a recombinant mammalian cell comprising a deoxyribonucleic acid encoding a trivalent antibody and secreting the trivalent antibody, the method comprising the steps of: a) providing a mammalian cell comprising an exogenous nucleotide sequence integrated at a single site within a locus of the genome of the mammalian cell, wherein the exogenous nucleotide sequence comprises a first recombination recognition sequence and a second recombination recognition sequence flanked by at least one first selection marker, and a third recombination recognition sequence located between the first recombination recognition sequence and the second recombination recognition sequence, and all of the recombination recognition sequences are different; b) introducing into the cell provided in a) the composition comprising two deoxyribonucleic acids according to any one of claims 36 to 66, wherein the two deoxyribonucleic acids comprise three different recombination recognition sequences and five to seven expression cassettes, wherein - The first deoxyribonucleic acid contains only the following expression cassette in the 5' to 3' direction (1) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first light chain, and - a first copy of the third recombination recognition sequence, or (2) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first light chain, and - a first copy of the third recombination recognition sequence, or (3) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of the third recombination recognition sequence, or (4) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of the third recombination recognition sequence, or (5) - a first recombination recognition sequence, - a first expression cassette encoding a first heavy chain, - a second expression cassette encoding a second heavy chain, - a third expression cassette encoding the first light chain, - a fourth expression cassette encoding a second light chain, and - a first copy of the third recombination recognition sequence, or (6) - a first recombination recognition sequence, - a first expression cassette encoding a first light chain, - a second expression cassette encoding a first light chain, - a third expression cassette encoding the first heavy chain, and - a first copy of a third recombination recognition sequence, and - the second deoxyribonucleic acid comprises in the 5' to 3' direction (1) - a second copy of the third recombination recognition sequence, - a fourth expression cassette encoding the second heavy chain, - a fifth expression cassette encoding a second light chain, and - a second recombination recognition sequence, or (2) - a second copy of the third recombination recognition sequence, - a fourth expression cassette encoding the second heavy chain, - a fifth expression cassette encoding the second light chain, - a sixth expression cassette encoding the second light chain, and - a second recombination recognition sequence, or (3) - a second copy of the third recombination recognition sequence, - a fifth expression cassette encoding a second light chain, and - a second recombination recognition sequence, or (4) - a second copy of the third recombination recognition sequence, - a fifth expression cassette encoding the first heavy chain, - a sixth expression cassette encoding the second light chain, and - a second recombination recognition sequence, or (5) - a second copy of the third recombination recognition sequence, - a fifth expression cassette encoding the second heavy chain, - a sixth expression cassette encoding the second light chain, - a seventh expression cassette encoding the second light chain, and - a second recombination recognition sequence, or (6) - a second copy of the third recombination recognition sequence, - a fourth expression cassette encoding the second heavy chain, - a fifth expression cassette encoding the second light chain, - a sixth expression cassette encoding the second light chain, and - a second recombination recognition sequence, wherein the first heavy chain comprises in the CH3 domain the mutation T366W according to Kabat numbering and the second heavy chain comprises in the CH3 domain the mutations T366S, L368A and Y407V according to Kabat numbering, or vice versa; in - the first heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a first light chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, - the second heavy chain comprises, from N-terminus to C-terminus, a first heavy chain variable domain, a CH1 domain, a hinge region, a CH2 domain and a CH3 domain, - the first light chain comprises, from N-terminus to C-terminus, a second heavy chain variable domain and a CL domain, and - the second light chain comprises, from N-terminus to C-terminus, a second light chain variable domain and a CL domain, wherein the first heavy chain variable domain and the second light chain variable domain form a first binding site, and the second heavy chain variable domain and the first light chain variable domain form a second binding site; wherein each of the expression cassettes comprises the same promoter, coding sequence and the same polyadenylation signal sequence in the 5' to 3' direction, wherein the first to third recombination recognition sequences of the first deoxyribonucleic acid and the second deoxyribonucleic acid match the first to third recombination recognition sequences on the integrated exogenous nucleotide sequence, wherein the 5' terminal portion and the 3' terminal portion of the expression cassette encoding one second selection marker when taken together form a functional expression cassette for said one second selection marker; c) i) is introduced simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b); or ii) Then introduce one or more recombinases, wherein the one or more recombinases recognize the recombination recognition sequences of the first deoxyribonucleic acid and the second deoxyribonucleic acid; as well as d) selecting cells expressing said second selection marker and secreting said trivalent antibody, Thereby, a recombinant mammalian cell is produced which contains the deoxyribonucleic acid encoding the trivalent antibody and secretes the trivalent antibody.
68. The method of claim 67, wherein: Each of the expression cassettes comprises, in the 5' to 3' direction, the same promoter, the coding sequence and the same polyadenylation signal sequence followed by a terminator sequence.
69. The method according to claim 67, wherein said step c) is: c) i) is introduced simultaneously with the first deoxyribonucleic acid and the second deoxyribonucleic acid of b); or ii) Then introduce one or more recombinases, wherein the one or more recombinases recognize the recombination recognition sequences of the first deoxyribonucleic acid and the second deoxyribonucleic acid; and wherein the one or more recombinases perform two recombinase-mediated cassette exchanges.
Citation Information
Patent Citations
Altered antibodies
EP0307434A1
Multivalent antibodies and uses therefor
US20020004587A1
Target specific cross-linked heteroantibodies
US4676980A
Method for making heteromultimeric polypeptides
US5731168A
Bifunctional selectable fusion genes
WO1992008796A1
